{
  "questions": [
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34022131"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Non-coding region variants upstream of MEF2C cause severe developmental disorder through three distinct loss-of-function mechanisms.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34022131",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Clinical genetic testing of protein-coding regions identifies a likely causative variant in only around half of developmental disorder (DD) cases. The contribution of regulatory variation in non-coding regions to rare disease, including DD, remains very poorly understood. We screened 9,858 probands from the Deciphering Developmental Disorders (DDD) study for de novo mutations in the 5\u0027 untranslated regions (5\u0027 UTRs) of genes within which variants have previously been shown to cause DD through a dominant haploinsufficient mechanism. We identified four single-nucleotide variants and two copy-number variants upstream of MEF2C in a total of ten individual probands. We developed multiple bespoke and orthogonal experimental approaches to demonstrate that these variants cause DD through three distinct loss-of-function mechanisms, disrupting transcription, translation, and/or protein function. These non-coding region variants represent 23% of likely diagnoses identified in MEF2C in the DDD cohort, but these would all be missed in standard clinical genetics approaches. Nonetheless, these variants are readily detectable in exome sequence data, with 30.7% of 5\u0027 UTR bases across all genes well covered in the DDD dataset. Our analyses show that non-coding variants upstream of genes within which coding variants are known to cause DD are an important cause of severe disease and demonstrate that analyzing 5\u0027 UTRs can increase diagnostic yield. We also show how non-coding variants can help inform both the disease-causing mechanism underlying protein-coding variants and dosage tolerance of the gene.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34022131",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1608
        }
      ],
      "id": "61f80d5d882a024a1000003c",
      "type": "yesno",
      "body": "Do only changes in coding regions of MEF2C cause developmental disorders?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34494428",
        "http://www.ncbi.nlm.nih.gov/pubmed/34558200",
        "http://www.ncbi.nlm.nih.gov/pubmed/34780683"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34494428",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34558200",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Milvexian (BMS-986177/JNJ-70033093) is a small molecule, active-site inhibitor of factor XIa (FXIa) being developed to prevent and treat thrombotic events. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34558200",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Additional data are needed regarding the efficacy and safety of milvexian, an oral factor XIa inhibitor.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34780683",
          "offsetInBeginSection": 190,
          "offsetInEndSection": 294
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "CONCLUSIONS: Postoperative factor XIa inhibition with oral milvexian in patients undergoing knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34780683",
          "offsetInBeginSection": 1817,
          "offsetInEndSection": 2033
        }
      ],
      "id": "61f58de2882a024a1000000a",
      "type": "factoid",
      "body": "Which factor is inhibited by Milvexian?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34549432",
        "http://www.ncbi.nlm.nih.gov/pubmed/32324629",
        "http://www.ncbi.nlm.nih.gov/pubmed/32302642",
        "http://www.ncbi.nlm.nih.gov/pubmed/32079690",
        "http://www.ncbi.nlm.nih.gov/pubmed/32608278",
        "http://www.ncbi.nlm.nih.gov/pubmed/34509050"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "expression of the non-specific cytotoxic cell marker (granzyme B, grb)",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34549432",
          "offsetInBeginSection": 1122,
          "offsetInEndSection": 1192
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " cytotoxic protein-positive cells, such as granzyme B cells",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32324629",
          "offsetInBeginSection": 483,
          "offsetInEndSection": 542
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Granzyme B is known to be a serine protease contained in granules of cytotoxic T cells. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32302642",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "including cytotoxic T cells (CD8, Granzyme B, OX40, Ki67),\n",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32079690",
          "offsetInBeginSection": 473,
          "offsetInEndSection": 532
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Granzyme B is a serine protease that is secreted by Natural Killer (NK) cells and cytotoxic T lymphocytes during a cellular immune response and can induce apoptosis. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32608278",
          "offsetInBeginSection": 195,
          "offsetInEndSection": 361
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "markers of activated cytotoxic T lymphocytes (CD8, granzyme-B) ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34509050",
          "offsetInBeginSection": 444,
          "offsetInEndSection": 507
        }
      ],
      "id": "6217d9de3a8413c653000025",
      "type": "factoid",
      "body": "What is Granzyme B?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34160816",
        "http://www.ncbi.nlm.nih.gov/pubmed/34313732",
        "http://www.ncbi.nlm.nih.gov/pubmed/29322444"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "CircRNAs are a subclass of lncRNAs that have been found to be abundantly present in a wide range of species, including humans. CircRNAs are generally produced by a noncanonical splicing event called backsplicing that is dependent on the canonical splicing machinery, giving rise to circRNAs classified into three main categories: exonic circRNA, circular intronic RNA, and exon-intron circular RNA. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34160816",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 399
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Circular RNA (circRNA) is a large class of covalently closed circRNA.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34313732",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 69
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Human transcriptome contains a large number of circular RNAs (circRNAs) that are mainly produced by back splicing of pre-mRNA.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29322444",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126
        }
      ],
      "id": "62211c853a8413c65300006d",
      "type": "yesno",
      "body": "Is CircRNA produced by back splicing of exon, intron or both, forming exon or intron circRNA?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24062159",
        "http://www.ncbi.nlm.nih.gov/pubmed/22236810",
        "http://www.ncbi.nlm.nih.gov/pubmed/23133392",
        "http://www.ncbi.nlm.nih.gov/pubmed/17360754",
        "http://www.ncbi.nlm.nih.gov/pubmed/14600262"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Condensin aids sister chromatid decatenation by topoisomerase II.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24062159",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 65
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Anaphase bridges observed in cells lacking condensin are reminiscent of chromosome segregation failure after inactivation of topoisomerase II (topo II), the enzyme that removes catenanes persisting between sister chromatids following DNA replication. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24062159",
          "offsetInBeginSection": 216,
          "offsetInEndSection": 467
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Complete resolution, however, requires the condensin complex, a dependency that becomes more pronounced with increasing chromosome size.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24062159",
          "offsetInBeginSection": 1026,
          "offsetInEndSection": 1162
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "condensin prevents deleterious anaphase bridges during chromosome segregation by promoting sister chromatid decatenation.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24062159",
          "offsetInBeginSection": 1197,
          "offsetInEndSection": 1318
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We propose a model of how metaphase chromosomes could be shaped based on the enzymatic activities of condensin and topoisomerase II in overwinding and relaxation of the DNA fiber during mitosis.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22236810",
          "offsetInBeginSection": 578,
          "offsetInEndSection": 772
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "ondensin overwinding is an important requirement for intertwine resolution by topoisomerase II and, together with the inhibition of transcription, contributes to cytological mitotic chromosome appearance or \u0027condensation\u0027.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22236810",
          "offsetInBeginSection": 790,
          "offsetInEndSection": 1012
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We also found spindle force, anaphase, or cytokinesis to be dispensable. RSZ breakage, however, required genes encoding condensin subunits (YCG1, YSC4) and topoisomerase II (TOP2). ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133392",
          "offsetInBeginSection": 1241,
          "offsetInEndSection": 1422
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "BGLF4 also stimulates the decatenation activity of topoisomerase II, suggesting that it may induce chromosome condensation through condensin and topoisomerase II activation.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17360754",
          "offsetInBeginSection": 867,
          "offsetInEndSection": 1040
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "BGLF4 interacts with condensin complexes, the major components in mitotic chromosome assembly, and induces condensin phosphorylation at Cdc2 consensus motifs.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17360754",
          "offsetInBeginSection": 708,
          "offsetInEndSection": 866
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Condensin-dependent localisation of topoisomerase II to an axial chromosomal structure is required for sister chromatid resolution during mitosis.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14600262",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "condensin is required so that an axial chromatid structure can be organised where topoisomerase II can effectively promote sister chromatid resolution.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14600262",
          "offsetInBeginSection": 1533,
          "offsetInEndSection": 1684
        }
      ],
      "id": "5fe31323a43ad3127800004d",
      "type": "summary",
      "body": "How does condensin affect the function of topoisomeraseII?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34820336"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34820336",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "PI3K inhibitor, LY294002, can block PI3K/AKT signaling, further inhibit glycolysis to disturb ATP production, and finally induce cell apoptosis. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34820336",
          "offsetInBeginSection": 1507,
          "offsetInEndSection": 1652
        }
      ],
      "id": "6206c22ac9dfcb9c0900003e",
      "type": "factoid",
      "body": "Which signaling pathway does LY294002 inhibit?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34352207"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " Here we find METTL1 is frequently amplified and overexpressed in cancers and is associated with poor patient survival. METTL1 depletion causes decreased abundance of m7G-modified tRNAs and altered cell cycle and inhibits oncogenicity. Conversely, METTL1 overexpression induces oncogenic cell transformation and cancer. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34352207",
          "offsetInBeginSection": 227,
          "offsetInEndSection": 547
        }
      ],
      "id": "620c27e93a8413c653000006",
      "type": "yesno",
      "body": "Is METTL1 overexpression associated with better patient survival?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34587383",
        "http://www.ncbi.nlm.nih.gov/pubmed/34463470",
        "http://www.ncbi.nlm.nih.gov/pubmed/34159343",
        "http://www.ncbi.nlm.nih.gov/pubmed/34159344",
        "http://www.ncbi.nlm.nih.gov/pubmed/34347950",
        "http://www.ncbi.nlm.nih.gov/pubmed/34393218"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "BACKGROUND: In the phase 1-2 portion of an adaptive trial, REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of medical visits in patients with coronavirus disease 2019 (Covid-19).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34587383",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 245
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "REGEN-COV is a cocktail of two human IgG1 monoclonal antibodies (REGN10933 + REGN10987) that targets severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and has shown great promise to reduce the SARS-CoV-2 viral load in COVID-19 patients enrolled in clinical studies. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34463470",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 291
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Background: Casirivimab and imdevimab (REGEN-COV™) markedly reduces risk of hospitalization or death in high-risk individuals with Covid-19.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34159344",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "BACKGROUND: REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce the risk of hospitalization or death among high-risk persons with coronavirus disease 2019 (Covid-19).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34347950",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 261
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "In the US, the FDA has given Emergency Use Authorization (EUA) for two neutralizing therapeutic monoclonal antibody \u0027cocktails,\u0027 casirivimab and imdevimab (REGEN-COV), bamlanivimab and etesevimab, and one monotherapy, bamlanivimab, for prophylactic post-exposure therapy in individuals at high risk of progressing to severe COVID-19. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34393218",
          "offsetInBeginSection": 414,
          "offsetInEndSection": 748
        }
      ],
      "id": "61f58ef3882a024a1000000b",
      "type": "list",
      "body": "List monoclonal antibodies included in the REGEN-COV."
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33869605",
        "http://www.ncbi.nlm.nih.gov/pubmed/34339548",
        "http://www.ncbi.nlm.nih.gov/pubmed/31865540",
        "http://www.ncbi.nlm.nih.gov/pubmed/29216683"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Spectrum mutations of PRF1, UNC13D, STX11, and STXBP2 genes in Vietnamese patients with hemophagocytic lymphohistiocytosis.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34339548",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The presence of mutations in PRF1, UNC13D, STX11 and STXBP2 genes in homozygosis or compound heterozygosis results in immune deregulation. Most such cases lead to clinical manifestations of haemophagocytic lymphohistiocytosis (HLH).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31865540",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Adult onset type 2 familial hemophagocytic lymphohistiocytosis with PRF1 c.65delC/c.163C\u003eT compound heterozygous mutations: A case report.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33869605",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Deleterious mutations in PRF1 result in lethal, childhood disease, familial hemophagocytic lymphohistiocytosis type 2 (FHL 2).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29216683",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 138
        }
      ],
      "id": "6217db1b3a8413c653000027",
      "type": "factoid",
      "body": "Which disease is caused by mutations in the gene PRF1?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32507413",
        "http://www.ncbi.nlm.nih.gov/pubmed/33433870"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Loss-of-function mutations in the gene encoding for the protein progranulin (PGRN), GRN, are one of the major genetic abnormalities involved in frontotemporal lobar degeneration.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32507413",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Numerous kindreds with familial frontotemporal lobar degeneration have been linked to mutations in microtubule-associated protein tau (MAPT) or progranulin (GRN) genes.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33433870",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168
        }
      ],
      "id": "62211f453a8413c653000072",
      "type": "factoid",
      "body": "What protein is encoded by the GRN gene?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21685894",
        "http://www.ncbi.nlm.nih.gov/pubmed/22573616",
        "http://www.ncbi.nlm.nih.gov/pubmed/24832538"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Opposing effects of Tcf3 and Tcf1 control Wnt stimulation of embryonic stem cell self-renewal.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21685894",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Interestingly, both Tcf3-β-catenin and Tcf1-β-catenin interactions contributed to Wnt stimulation of self-renewal and gene expression, and the combination of Tcf3 and Tcf1 recruited Wnt-stabilized β-catenin to Oct4 binding sites on ESC chromatin",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21685894",
          "offsetInBeginSection": 777,
          "offsetInEndSection": 1022
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "In contrast to β-catenin-dependent functions described for Tcf1, Tcf4 and Lef1, the known embryonic functions for Tcf3 in mice, frogs and fish are consistent with β-catenin-independent repressor activity. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22573616",
          "offsetInBeginSection": 139,
          "offsetInEndSection": 344
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Tcf3 directly represses transcription of Lef1, which is stimulated by Wnt/β-catenin activity. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22573616",
          "offsetInBeginSection": 1070,
          "offsetInEndSection": 1164
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Tcf3 represses Wnt-β-catenin signaling and maintains neural stem cell population during neocortical development",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24832538",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We also found that Wnt signal stimulation reduces the level of Tcf3, and increases those of Tcf1 (also known as Tcf7) and Lef1, positive mediators of Wnt signaling, in NPCs.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24832538",
          "offsetInBeginSection": 1114,
          "offsetInEndSection": 1287
        }
      ],
      "id": "5fdb4176a43ad3127800001a",
      "type": "summary",
      "body": "What is the difference in the roles of Tcf1 and Tcf3 during development?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31828807"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Grapefruit (Citrus paradisi) juice enhances the oral bioavailability of drugs that are metabolized by intestinal cytochrome P450 3A4 (CYP3A4). Patients are advised to avoid drinking grapefruit juice to prevent this drug-grapefruit juice interaction.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31828807",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 261
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The encapsulation of BG and DHBG by γCD and the resulting attenuation of the inhibition of CYP3A activity by grapefruit juice may be applicable to juice processing for preventing drug-grapefruit juice interactions.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31828807",
          "offsetInBeginSection": 1175,
          "offsetInEndSection": 1389
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The inhibition of CYP3A by grapefruit juice was significantly attenuated by processing particularly with γCD. Similar attenuation effects by γCD were observed in the cases of BG and DHBG. Furthermore, BG and DHBG were suggested to be strongly encapsulated in the cavity of γCD.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31828807",
          "offsetInBeginSection": 886,
          "offsetInEndSection": 1163
        }
      ],
      "id": "62058382c9dfcb9c09000031",
      "type": "summary",
      "body": "Why mix γ-cyclodextrin with grapefruit juice?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34099552"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "ALS- and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34099552",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84
        }
      ],
      "id": "62190ca03a8413c653000035",
      "type": "factoid",
      "body": "What is disrupted by ALS- and FTD-associated missense mutations in TBK1?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33775030",
        "http://www.ncbi.nlm.nih.gov/pubmed/33792213",
        "http://www.ncbi.nlm.nih.gov/pubmed/33936913",
        "http://www.ncbi.nlm.nih.gov/pubmed/34401233",
        "http://www.ncbi.nlm.nih.gov/pubmed/32335518",
        "http://www.ncbi.nlm.nih.gov/pubmed/32257483",
        "http://www.ncbi.nlm.nih.gov/pubmed/32716145"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Morel-Lavallée lesion is a post-traumatic degloving cyst, usually filled with blood, lymph or necrotic tissue, which mostly develops in the area around greater trochanter.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33775030",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "CONCLUSIONS: Characteristic features of ML lesion include a fusiform fluid collection between the subcutaneous fat and the underlying fascia after shearing injury. Six types can be differentiated on MRI, with the seroma, the subacute hematoma and the chronic organizing hematoma being the commonest.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33792213",
          "offsetInBeginSection": 1295,
          "offsetInEndSection": 1594
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Morel-Lavallée lesion (MLL) is a closed degloving soft-tissue injury that results in the accumulation of a hemolymphatic fluid between the skin/superficial fascia and the deep fascia. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33936913",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The Morel-Lavallée lesion is a closed internal soft-tissue degloving injury. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34401233",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "INTRODUCTION: A Morel-Lavallée lesion (MLL) is a rare and aesthetically concerning condition caused by a shearing force between subcutaneous fat and underlying fascia. Subsequent seroma formation occurs after the initial trauma of a crush injury, ligamentous sprain, or abdominal liposuction. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32335518",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 293
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Morel-Lavallée lesion (MLL) is a degloving injury in soft tissues caused by shear force accompanying trauma. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32257483",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "A particular case of lesion in which seroma occurs is the Morel-Lavallée lesion (MLL), which is an uncommon closed soft-tissue degloving injury that develops after high-energy trauma or crush injury where shearing forces separate the subcutaneous tissue from the underlying fascia.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32716145",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 404
        }
      ],
      "id": "61f59012882a024a1000000c",
      "type": "summary",
      "body": "What is Morel–Lavallée lesion?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34509145",
        "http://www.ncbi.nlm.nih.gov/pubmed/33272761"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Patatin, the major protein found in potatoes, was purified and shows several isoforms. The essential amino acid content of patatin was ashighas 76%, indicating that it is a valuable protein source. Patatin was an O-linked glycoprotein that contained fucose monosaccharides, as well as mannose, rhamnose, glucose, galactose, xylose, and arabinose. Patatin had a fucosylated glycan structural feature, which strongly bound AAL (Aleuria aurantia Leukoagglutinin), a known fucose binding lectin. Moreover, thelipid metabolism regulatory effects of patatin on the fat catabolism, fat absorption, and inhibition of lipase activity were measured after high-fat feeding of zebrafish larvae. Results revealed that 37.0 μg/mL patatin promoted 23% lipid decomposition metabolism. Meanwhile patatin could inhibite lipase activity and fat absorption, whose effects accounted for half that of a positive control drug. Our findings suggest that patatin, a fucosylated glycoprotein, could potentially be used as a naturalactiveconstituent with anti-obesity effects.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33272761",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1049
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Potato patatin is considered a valuable plant protein by the food industry for its exceptional functional properties and nutritional value. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34509145",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140
        }
      ],
      "id": "6217e7a63a8413c653000033",
      "type": "summary",
      "body": "What is known about the protein patatin?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28289025",
        "http://www.ncbi.nlm.nih.gov/pubmed/34474834",
        "http://www.ncbi.nlm.nih.gov/pubmed/34546758",
        "http://www.ncbi.nlm.nih.gov/pubmed/34216464",
        "http://www.ncbi.nlm.nih.gov/pubmed/34257648"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Primaquine (PQ) not only eliminates P. falciparum gametocytes but also kills liver dormant forms of P. vivax and P. ovale. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34257648",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The effect of primaquine in preventing P. vivax relapses from dormant stages is well established.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34216464",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 109
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "the wide use of PQ to treat liver-stage malaria. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34546758",
          "offsetInBeginSection": 83,
          "offsetInEndSection": 132
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Primaquine (PQ) is one of the most widely used antimalarial drugs. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34474834",
          "offsetInBeginSection": 512,
          "offsetInEndSection": 579
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Low-dose primaquine is recommended to prevent Plasmodium falciparum malaria transmission",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28289025",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88
        }
      ],
      "id": "621ecac13a8413c65300005f",
      "type": "factoid",
      "body": "What is the mode of action of primaquine?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29106613",
        "http://www.ncbi.nlm.nih.gov/pubmed/30286773",
        "http://www.ncbi.nlm.nih.gov/pubmed/26868282",
        "http://www.ncbi.nlm.nih.gov/pubmed/27734896",
        "http://www.ncbi.nlm.nih.gov/pubmed/24526713"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "3DIV: A 3D-genome Interaction Viewer and database.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29106613",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 50
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "In order to overcome these limitations, we constructed a database named 3DIV (a 3D-genome Interaction Viewer and database) that provides a list of long-range chromatin interaction partners for the queried locus with genomic and epigenomic annotations.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29106613",
          "offsetInBeginSection": 445,
          "offsetInEndSection": 696
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "The 3D Genome Browser: a web-based browser for visualizing 3D genome organization and long-range chromatin interactions.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30286773",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "we introduce the 3D Genome Browser, http://3dgenome.org , which allows users to conveniently explore both their own and over 300 publicly available chromatin interaction data of different types.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30286773",
          "offsetInBeginSection": 6,
          "offsetInEndSection": 200
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "GMOL: An Interactive Tool for 3D Genome Structure Visualization.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26868282",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 64
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "ere we present a desktop application, known as GMOL, designed to effectively visualize genome structures so that researchers may better analyze genomic data. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26868282",
          "offsetInBeginSection": 496,
          "offsetInEndSection": 654
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "3Disease Browser: A Web server for integrating 3D genome and disease-associated chromosome rearrangement data.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27734896",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We also develop a Web server (3Disease Browser, http://3dgb.cbi.pku.edu.cn/disease/) for integrating and visualizing disease-associated CR events and chromosomal 3D structure.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27734896",
          "offsetInBeginSection": 723,
          "offsetInEndSection": 898
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "The 3DGD: a database of genome 3D structure",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24526713",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 43
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We built 3DGD (3D Genome Database), a database that currently collected Hi-C data on four species, for easy accessing and visualization of chromatin 3D structure data.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24526713",
          "offsetInBeginSection": 294,
          "offsetInEndSection": 461
        }
      ],
      "id": "5fe3131da43ad31278000049",
      "type": "list",
      "body": "Which databases are devoted to 3D genome interactions?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33651100"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Here we describe a fully human bsAb (REGN5458) that binds to B-cell maturation antigen (BCMA) and CD3, and compare its antitumor activities vs those of anti-BCMA CAR T cells to identify differences in efficacy and mechanism of action. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33651100",
          "offsetInBeginSection": 183,
          "offsetInEndSection": 418
        }
      ],
      "id": "621218fc3a8413c653000014",
      "type": "list",
      "body": "Where does REGN5458 bind to?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34061450"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "KCNT2 variants resulting in substitutions affecting the Arg190 residue have been shown to cause epileptic encephalopathy and a recognizable facial gestalt. We report two additional individuals with intellectual disability, dysmorphic features, hypertrichosis, macrocephaly and the same de novo KCNT2 missense variants affecting the Arg190 residue as previously described. Notably, neither patient has epilepsy. Homology modeling of these missense variants revealed that they are likely to disrupt the stabilization of a closed channel conformation of KCNT2 resulting in a constitutively open state. This is the first report of pathogenic variants in KCNT2 causing a developmental phenotype without epilepsy.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34061450",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 707
        }
      ],
      "id": "61f80c37882a024a1000003b",
      "type": "yesno",
      "body": "Do mutations in KCNT2 only cause phenotypes with epilepsy?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26864508",
        "http://www.ncbi.nlm.nih.gov/pubmed/28209014",
        "http://www.ncbi.nlm.nih.gov/pubmed/27830291",
        "http://www.ncbi.nlm.nih.gov/pubmed/27377117",
        "http://www.ncbi.nlm.nih.gov/pubmed/24379574",
        "http://www.ncbi.nlm.nih.gov/pubmed/21305742",
        "http://www.ncbi.nlm.nih.gov/pubmed/19552719",
        "http://www.ncbi.nlm.nih.gov/pubmed/19242389"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Among the main oral manifestations of IBD are cobblestoning of the oral mucosa, labial swellings with vertical fissures, pyostomatitis vegetans, angular cheilitis, perioral erythema, and glossitis. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26864508",
          "offsetInBeginSection": 174,
          "offsetInEndSection": 372
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Pyostomatitis Vegetans: A Clue for Diagnosis of Silent Crohn\u0027s Disease.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28209014",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 71
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We present a case of Pyostomatitis vegetans involving gingiva and oral mucosa with no skin lesion which led to the diagnosis of Crohn\u0027s disease to emphasize important role of dentists in diagnosis of rare oral lesions and management of patients\u0027 systemic disease.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28209014",
          "offsetInBeginSection": 351,
          "offsetInEndSection": 614
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Moreover, in both CD and UC, there occur several other inflammatory skin conditions such as erythema nodosum, pyoderma gangrenosum, hidradenitis suppurativa, chronic oral aphthous disease, Sweet syndrome, pyostomatitis vegetans, and bowel-associated dermatosis-arthritis syndrome. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27830291",
          "offsetInBeginSection": 913,
          "offsetInEndSection": 1194
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Diffuse mucosal swelling, cobblestone mucosa, localised mucogingivitis, deep linear ulceration, fibrous tissue tags, polyps, nodules, pyostomatitis vegetans, and aphthous-like ulcers have been described in Crohn\u0027s disease. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27377117",
          "offsetInBeginSection": 280,
          "offsetInEndSection": 503
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Aphthous stomatitis and pyostomatitis vegetans are among non-specific oral manifestations of IBD.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24379574",
          "offsetInBeginSection": 513,
          "offsetInEndSection": 610
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Pyostomatitis vegetans (PV) is a rare, chronic mucocutaneous disorder associated with inflammatory bowel disease (IBD). Oral lesions of PV are distinct and present as multiple white or yellow pustules with an erythematous base that coalesce and undergo necrosis to form a typical \"snail tracks\" appearance. Two cases of PV associated with IBD--one with Crohn\u0027s disease (CD) and the other with ulcerative colitis (UC) are reported.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21305742",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 430
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " Oral involvement during IBD includes several types of lesions: the most common are aphthae; uncommon lesions include, among others, pyostomatitis vegetans and granulomatous lesions of CD. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19552719",
          "offsetInBeginSection": 292,
          "offsetInEndSection": 481
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Pyostomatitis vegetans (PV) is a rare condition characterized by pustules that affect the oral mucosa. It is a highly specific marker for inflammatory bowel disease and its correct recognition may lead to the diagnosis of ulcerative colitis or Crohn\u0027s disease. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19242389",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 261
        }
      ],
      "id": "61f593f8882a024a1000000f",
      "type": "yesno",
      "body": "Is there an association between pyostomatitis vegetans and Crohn\u0027s disease?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32901992",
        "http://www.ncbi.nlm.nih.gov/pubmed/32876809",
        "http://www.ncbi.nlm.nih.gov/pubmed/31570504",
        "http://www.ncbi.nlm.nih.gov/pubmed/31624776",
        "http://www.ncbi.nlm.nih.gov/pubmed/34662506"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " activated platelets, which carry peripheral serotonin,",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32901992",
          "offsetInBeginSection": 231,
          "offsetInEndSection": 286
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Platelet serotonin response was measured by serotonin augmented platelet aggregation and platelet serotonin receptor density. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32876809",
          "offsetInBeginSection": 753,
          "offsetInEndSection": 879
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "SERT was studied in the 1970s and 1980s using membrane vesicles isolated from blood platelets.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31570504",
          "offsetInBeginSection": 495,
          "offsetInEndSection": 589
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "platelet-dense granules contain neurotransmitters such as serotonin and gamma-aminobutyric acid. Molecular players controlling granule formation and secretion are",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31624776",
          "offsetInBeginSection": 685,
          "offsetInEndSection": 847
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Platelets transport and store virtually all plasma serotonin in dense granules",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34662506",
          "offsetInBeginSection": 383,
          "offsetInEndSection": 461
        }
      ],
      "id": "6217e1ac3a8413c653000031",
      "type": "yesno",
      "body": "Is serotonin transported by platelets?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33482249",
        "http://www.ncbi.nlm.nih.gov/pubmed/33571591",
        "http://www.ncbi.nlm.nih.gov/pubmed/33681296",
        "http://www.ncbi.nlm.nih.gov/pubmed/33728352",
        "http://www.ncbi.nlm.nih.gov/pubmed/31487436",
        "http://www.ncbi.nlm.nih.gov/pubmed/32023817"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Nuclear translocation of large proteins is mediated through specific protein carriers, collectively named karyopherins (importins, exportins and adaptor proteins).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33482249",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 175
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Karyopherins mediate the macromolecular transport between the cytoplasm and the nucleus and participate in cancer progression.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33571591",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Transportin-1 (Trn1), also known as karyopherin-β2 (Kapβ2), is probably the best-characterized nuclear import receptor of the karyopherin-β family after Importin-β",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33681296",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Karyopherin alpha 2 (KPNA2), a member of the nuclear transporter family, is elevated in multiple human cancers and accelerates carcinogenesis.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33728352",
          "offsetInBeginSection": 251,
          "offsetInEndSection": 393
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Nuclear import of proteins relies on nuclear import receptors called importins/karyopherins (Kaps), whose functions were reported in yeasts, fungi, plants, and animal cells, including cell cycle control, morphogenesis, stress sensing/response, and also fungal pathogenecity. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31487436",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 275
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "In eukaryotic cells, nucleocytoplasmic trafficking of macromolecules is largely mediated by Karyopherin β/Importin (KPNβ or Impβ) nuclear transport factors, and they import and export cargo proteins or RNAs via the nuclear pores across the nuclear envelope, consequently effecting the cellular signal cascades in response to pathogen attack and environmental cues. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32023817",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 365
        }
      ],
      "id": "6221209b3a8413c653000074",
      "type": "factoid",
      "body": "Proteins in the karyopherin family (Kaps) are associated with what cellular process?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22732409",
        "http://www.ncbi.nlm.nih.gov/pubmed/21914464",
        "http://www.ncbi.nlm.nih.gov/pubmed/16469316",
        "http://www.ncbi.nlm.nih.gov/pubmed/11333024",
        "http://www.ncbi.nlm.nih.gov/pubmed/26415210"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Intronless genes (IGs) constitute approximately 3% of the human genome.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22732409",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 71
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Intronless genes (IGs) fraction varies between 2.7 and 97.7% in eukaryotic genomes. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21914464",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "608 of these genes have intronless human orthologs",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16469316",
          "offsetInBeginSection": 477,
          "offsetInEndSection": 527
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Intronless genes, which constitute 3 percent of the human genome, differ from intron-containing genes in evolution and function.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26415210",
          "offsetInBeginSection": 105,
          "offsetInEndSection": 233
        }
      ],
      "id": "5fe1fc84a43ad31278000036",
      "type": "factoid",
      "body": "What percentage of human genes have no introns?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34549911"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "In this review, we highlight the current US Food and Drug Administration approved MoAbs, namely, belantamab mafodotin, daratumumab, elotuzumab, and isatuximab. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34549911",
          "offsetInBeginSection": 400,
          "offsetInEndSection": 560
        }
      ],
      "id": "62121a463a8413c653000015",
      "type": "list",
      "body": "What are the currently FDA approved monoclonal antibodies for myeloma?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34244665"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Biallelic variants in PCDHGC4 cause a novel neurodevelopmental syndrome with progressive microcephaly, seizures, and joint anomalies.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34244665",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We show that biallelic variants in PCDHGC4 are causing a novel autosomal recessive neurodevelopmental disorder and link PCDHGC4 as a member of the clustered PCDH family to a Mendelian disorder in humans.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34244665",
          "offsetInBeginSection": 1338,
          "offsetInEndSection": 1541
        }
      ],
      "id": "61f563f7882a024a10000006",
      "type": "factoid",
      "body": "What is caused by biallelic variants in PCDHGC4?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34531332",
        "http://www.ncbi.nlm.nih.gov/pubmed/34819468",
        "http://www.ncbi.nlm.nih.gov/pubmed/34706189"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "It seems that monoclonal antibodies (e.g., low dosage bamlanivimab, baricitinib, imatinib, and sotrovimab) are a better choice for treating severe or non-severe COVID-19 patients. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34531332",
          "offsetInBeginSection": 2582,
          "offsetInEndSection": 2762
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The Food and Drug Administration has granted emergency use authorization to sotrovimab for the treatment of mild to moderate COVID-19 in patients at increased risk for progression to severe illness.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34819468",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34706189",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 in high-risk patients early in the course of disease",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34706189",
          "offsetInBeginSection": 159,
          "offsetInEndSection": 317
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "CONCLUSIONS: Among high-risk patients with mild-to-moderate Covid-19, sotrovimab reduced the risk of disease progression.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34706189",
          "offsetInBeginSection": 1611,
          "offsetInEndSection": 1732
        }
      ],
      "id": "61f59592882a024a10000010",
      "type": "yesno",
      "body": "Is Sotrovimab effective for COVID-19?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28498270",
        "http://www.ncbi.nlm.nih.gov/pubmed/29076638",
        "http://www.ncbi.nlm.nih.gov/pubmed/20856818",
        "http://www.ncbi.nlm.nih.gov/pubmed/18410381"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "otoconia matrix protein, otolin-1",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28498270",
          "offsetInBeginSection": 138,
          "offsetInEndSection": 171
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Otolin-1 is a collagen-like protein expressed in the inner ear of vertebrates. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29076638",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Mammalian Otolin: a multimeric glycoprotein specific to the inner ear that interacts with otoconial matrix protein Otoconin-90 and Cerebellin-1",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20856818",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "binds to otolin-1 and forming matrix protein architectures",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18410381",
          "offsetInBeginSection": 1558,
          "offsetInEndSection": 1616
        }
      ],
      "id": "621b5bcc3a8413c65300003d",
      "type": "yesno",
      "body": "Is Otolin-1 a matrix protein?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31513439",
        "http://www.ncbi.nlm.nih.gov/pubmed/34511878",
        "http://www.ncbi.nlm.nih.gov/pubmed/33471572",
        "http://www.ncbi.nlm.nih.gov/pubmed/34188445"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Faricimab, a bispecific antibody that inhibits VEGF-A and Ang-2, is in phase 3 trials for nAMD and DME.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31513439",
          "offsetInBeginSection": 438,
          "offsetInEndSection": 541
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Faricimab is a bispecific antibody that has been developed as an inhibitor of both VEGF and Ang2",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34511878",
          "offsetInBeginSection": 215,
          "offsetInEndSection": 311
        }
      ],
      "id": "621eb93b3a8413c65300005b",
      "type": "list",
      "body": "List the drug targets of Faricimab?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30089468",
        "http://www.ncbi.nlm.nih.gov/pubmed/26861889",
        "http://www.ncbi.nlm.nih.gov/pubmed/28928151",
        "http://www.ncbi.nlm.nih.gov/pubmed/29147672",
        "http://www.ncbi.nlm.nih.gov/pubmed/29548296",
        "http://www.ncbi.nlm.nih.gov/pubmed/29945683",
        "http://www.ncbi.nlm.nih.gov/pubmed/9343185"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Readthrough activation of early adenovirus E1b gene transcription",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9343185",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 65
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Using the rigorous methodology Cap-Seq, we demonstrated that DoGs result from transcriptional readthrough, not de novo initiation. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29945683",
          "offsetInBeginSection": 429,
          "offsetInEndSection": 560
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Rather it is, as we originally demonstrated, transcriptional readthrough that leads to the formation of DoGs.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29945683",
          "offsetInBeginSection": 1662,
          "offsetInEndSection": 1771
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Previous studies demonstrated that massive induction of transcriptional readthrough generates downstream of gene-containing transcripts (DoGs) in cells under stress condition",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29548296",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " Importantly, Ca2+ signaling mediates reduced transcription termination in response to certain stress conditions. This reduction allows readthrough transcription, generating a highly inducible and diverse class of downstream of gene containing transcripts (DoGs) that we have recently described.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29147672",
          "offsetInBeginSection": 618,
          "offsetInEndSection": 913
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Finally, we examine genomic features of readthrough transcription and observe a unique chromatin signature typical of DoG-producing regions, suggesting that readthrough transcription is associated with the maintenance of an open chromatin state.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28928151",
          "offsetInBeginSection": 1598,
          "offsetInEndSection": 1843
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We recently discovered that stress-induced transcriptional readthrough generates very long downstream of gene containing transcripts (DoGs), which may explain up to 20% of intergenic transcription. DoGs are induced by osmotic stress at the level of transcription by a mechanism that depends on calcium release from the endoplasmic reticulum mediated by IP3 receptors. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26861889",
          "offsetInBeginSection": 279,
          "offsetInEndSection": 647
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Furthermore, the readthrough response to stress has thus far not been investigated outside of mammalian species, and the occurrence of readthrough in many physiological and disease conditions remains to be explored",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30089468",
          "offsetInBeginSection": 444,
          "offsetInEndSection": 658
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We further demonstrate the use of the DoGFinder software package on a new publically available RNA-seq dataset, and discover DoG induction in human PME cells following hypoxia - a previously unknown readthrough inducing stress type.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30089468",
          "offsetInBeginSection": 1171,
          "offsetInEndSection": 1403
        }
      ],
      "id": "5fe31316a43ad31278000043",
      "type": "factoid",
      "body": "What induces downstream of gene (DoG) readthrough transcription?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34875308"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "These novel insights into the rHDL-apoE3 functions suggest a potential clinical use to promote re-endothelialization and retard development of atherosclerosis.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34875308",
          "offsetInBeginSection": 3531,
          "offsetInEndSection": 3690
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The capacity of rHDL-apoE3 to stimulate EC migration was assessed by wound healing and transwell migration assays. The contribution of MEK1/2, PI3K and the transcription factor ID1 in rHDL-apoE3-induced EC migration and activation of EC migration-related effectors was assessed using specific inhibitors (PD98059: MEK1/2, LY294002: PI3K) and siRNA-mediated gene silencing, respectively. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34875308",
          "offsetInBeginSection": 1245,
          "offsetInEndSection": 1632
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "In addition, rHDL-apoE3 stimulated migration of HCAEC and EA.hy926 cells, and the migration was markedly attenuated in the presence of PD98059 or LY294002.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34875308",
          "offsetInBeginSection": 2436,
          "offsetInEndSection": 2591
        }
      ],
      "id": "6206b5a8c9dfcb9c0900003a",
      "type": "factoid",
      "body": "What is the effect of rHDL-apoE3 on endothelial cell migration?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34117353"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "AGO2 localizes to cytokinetic protrusions in a p38-dependent manner and is needed for accurate cell division.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34117353",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We suggest that AGO2 is part of a regulatory mechanism triggered by cytokinetic stress to generate the appropriate micro-environment for local transcript homeostasis.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34117353",
          "offsetInBeginSection": 871,
          "offsetInEndSection": 1037
        }
      ],
      "id": "620aedee3a8413c653000001",
      "type": "yesno",
      "body": "Is AGO2 related to cytokinesis?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26521192",
        "http://www.ncbi.nlm.nih.gov/pubmed/24862753"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Hampton\u0027s hump in a patient with endocarditis and septic emboli.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26521192",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 64
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We discuss a case of a 20-year-old woman presenting with chest pain found to have a Hampton\u0027s hump on chest x-ray and corresponding wedge infarct on computed tomographic scan. Contrary to our suspicion that this febrile and tachycardic patient had a pulmonary embolism, she was later determined to have a septic embolus secondary to endocarditis. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26521192",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 347
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Chest radiograph showed a peripheral-based opacity in the right lower zone, which was not seen in a previous study done three months ago, suggestive of Hampton\u0027s hump. The D-dimer level was raised. Computed tomography pulmonary angiography confirmed the diagnosis of pulmonary embolism in a right lower lobe segmental branch, with adjacent collapsed lung, consistent with lung infarction. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24862753",
          "offsetInBeginSection": 177,
          "offsetInEndSection": 566
        }
      ],
      "id": "61f5ee57882a024a10000012",
      "type": "factoid",
      "body": "Hampton’s hump is characteristic to which disease?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34752953",
        "http://www.ncbi.nlm.nih.gov/pubmed/34520819",
        "http://www.ncbi.nlm.nih.gov/pubmed/34535017",
        "http://www.ncbi.nlm.nih.gov/pubmed/34557196"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Indoleamine 2,3-dioxygenase 1 (IDO1), a known immunosuppressive enzyme that catalyzes the rate-limiting step in the oxidation of tryptophan (Trp) to kynurenine (Kyn), has received increasing attention as an attractive immunotherapeutic target for cancer therapy. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34752953",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 263
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzing the conversion of tryptophan (Trp) to kynurenine (Kyn) in kynurenine pathway (KP) is involved in the immunosuppression in pancreatic cancer (PC), but the value of IDO1 as an independent prognostic marker for PC is uncertain. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34520819",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 273
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Indoleamine 2,3-dioxygenase 1 (IDO1), which is negatively regulated by the BIN1 proto-oncogene, is an interferon (IFN)-γ-inducible mediator of immune tolerance. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34535017",
          "offsetInBeginSection": 180,
          "offsetInEndSection": 341
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Indoleamine 2,3-dioxygenase 1 (IDO1) is a normal endogenous mechanism of acquired peripheral immune tolerance and may therefore be tumor-promoting. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34557196",
          "offsetInBeginSection": 72,
          "offsetInEndSection": 220
        }
      ],
      "id": "6217d9493a8413c653000022",
      "type": "factoid",
      "body": "What is the activity of Indoleamine 2,3-dioxygenase 1."
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17760832",
        "http://www.ncbi.nlm.nih.gov/pubmed/14732047",
        "http://www.ncbi.nlm.nih.gov/pubmed/10321993",
        "http://www.ncbi.nlm.nih.gov/pubmed/11029048",
        "http://www.ncbi.nlm.nih.gov/pubmed/10678991"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Macropinocytosis defines a series of events initiated by extensive plasma membrane reorganization or ruffling to form an external macropinocytic structure that is then enclosed and internalized. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17760832",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Macropinocytosis is a form of endocytosis that accompanies cell surface ruffling.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14732047",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 81
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Modified LDLs are internalized by macrophages in part via macropinocytosis.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10321993",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 75
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Macropinocytosis results from the closure of lamellipodia generated by membrane ruffling, thereby reflecting cortical actin dynamics. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11029048",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Gonococcal entry into primary human urethral epithelial cells (HUEC) can occur by macropinocytosis.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10678991",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Macropinocytosis as a mechanism of entry into primary human urethral epithelial cells by Neisseria gonorrhoeae.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10678991",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111
        }
      ],
      "id": "62211ebc3a8413c653000071",
      "type": "factoid",
      "body": "What is the purpose of  Macropinocytosis?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28943376",
        "http://www.ncbi.nlm.nih.gov/pubmed/29556078",
        "http://www.ncbi.nlm.nih.gov/pubmed/30346517",
        "http://www.ncbi.nlm.nih.gov/pubmed/27103098",
        "http://www.ncbi.nlm.nih.gov/pubmed/28325876",
        "http://www.ncbi.nlm.nih.gov/pubmed/28642936",
        "http://www.ncbi.nlm.nih.gov/pubmed/27358863",
        "http://www.ncbi.nlm.nih.gov/pubmed/24391509",
        "http://www.ncbi.nlm.nih.gov/pubmed/25506301",
        "http://www.ncbi.nlm.nih.gov/pubmed/22722833",
        "http://www.ncbi.nlm.nih.gov/pubmed/29216381",
        "http://www.ncbi.nlm.nih.gov/pubmed/27056411"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "de novo gene birth remains poorly understood, mainly because translation of sequences devoid of genes, or \u0027non-genic\u0027 sequences, is expected to produce insignificant polypeptides rather than proteins with specific biological functions.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22722833",
          "offsetInBeginSection": 239,
          "offsetInEndSection": 474
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Testing this model at the genome scale in Saccharomyces cerevisiae, we detect translation of hundreds of short species-specific open reading frames (ORFs) located in non-genic sequences. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22722833",
          "offsetInBeginSection": 668,
          "offsetInEndSection": 855
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We identify ~1,900 candidate proto-genes among S. cerevisiae ORFs and find that de novo gene birth from such a reservoir may be more prevalent than sporadic gene duplication",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22722833",
          "offsetInBeginSection": 1178,
          "offsetInEndSection": 1351
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Although the origin of such \"orphan\" genes remains unclear, they are thought to be involved in species-specific adaptive processes. Here, we analyzed seven orphan genes (MoSPC1 to MoSPC7) prioritized based on in planta expressed sequence tag data in the rice blast fungus, Magnaporthe oryzae.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25506301",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 383
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Based on these results, the four orphan genes may be products of de novo gene birth processes, and their adaptive potential is in the course of being tested for retention or extinction through natural selection.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25506301",
          "offsetInBeginSection": 1087,
          "offsetInEndSection": 1298
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "NCYM is the first de novo evolved protein known to act as an oncopromoting factor in human cancer, and suggest that de novo evolved proteins may functionally characterize human disease.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24391509",
          "offsetInBeginSection": 1741,
          "offsetInEndSection": 1926
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "De novo gene-birth contributes to shorter exons, longer introns, and higher exon-density in species-specific genes relative to conserved genes.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27358863",
          "offsetInBeginSection": 2580,
          "offsetInEndSection": 2723
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The phenomenon of de novo gene birth from junk DNA is surprising, because random polypeptides are expected to be toxic.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28642936",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "These targets regulated diverse biological processes including nutrient sensing and the DNA damage response, and implicated Vts1 in de novo gene \"birth.\"",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28325876",
          "offsetInBeginSection": 919,
          "offsetInEndSection": 1072
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Many modern analysis pipelines use significant sequence similarity scores (p- or E-values) and the ranked order of BLAST matches to test a wide range of hypotheses concerning homology, orthology, the timing of de novo gene birth/death and gene family",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27103098",
          "offsetInBeginSection": 175,
          "offsetInEndSection": 425
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "The Majority of Novel Protein-Coding Genes Identified with Phylostratigraphy Are Old Genes or Recent Duplicates.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30346517",
          "offsetInBeginSection": 27,
          "offsetInEndSection": 139
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Using a combination of synteny information and sequence similarity searches, I show that ∼60% of the remaining 381 putative de novo genes share homology with genes from other vertebrates, originated through gene duplication, and/or share no synteny information with nonrodent mammals.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30346517",
          "offsetInBeginSection": 904,
          "offsetInEndSection": 1188
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We find hundreds of open reading frames that are translated and that show no evolutionary conservation or selective constraints.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29556078",
          "offsetInBeginSection": 600,
          "offsetInEndSection": 728
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " The AQP2 gene consists of four exons, but the alternative AQP2 gene lacks the fourth exon and instead has a longer third exon that includes the original third exon and a part of the original third intron.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28943376",
          "offsetInBeginSection": 318,
          "offsetInEndSection": 523
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Nonetheless we identified 35 de novo genes: 16 human-specific; 5 human and chimpanzee specific; and 14 that originated prior to the divergence of human, chimpanzee, and gorilla and are found in all three genomes",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27056411",
          "offsetInBeginSection": 560,
          "offsetInEndSection": 771
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "De novo gene evolution of antifreeze glycoproteins in codfishes revealed by whole genome sequence data.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29216381",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "New genes can arise through duplication of a pre-existing gene or de novo from non-coding DNA, providing raw material for evolution of new functions in response to a changing environment. A prime example is the independent evolution of antifreeze glycoprotein genes (afgps) in the Arctic codfishes and Antarctic notothenioids to prevent freezing.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29216381",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 346
        }
      ],
      "id": "5eb422150d431b5f73000009",
      "type": "factoid",
      "body": "Which was the first species in which a de novo gene emergence (\"gene birth\") was reported?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24925412"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The chromones are a class of chemical compounds characterised by the presence of the structure 5:6 benz-1:4-pyrone in their chemical make-up. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24925412",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142
        }
      ],
      "id": "6206c428c9dfcb9c0900003f",
      "type": "summary",
      "body": "What are chromones?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33902106"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33902106",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 76
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Here we present the identification and characterization of STM2457, a highly potent and selective first-in-class catalytic inhibitor of METTL3, and a crystal structure of STM2457 in complex with METTL3-METTL14. Treatment of tumours with STM2457 leads to reduced AML growth and an increase in differentiation and apoptosis. These cellular effects are accompanied by selective reduction of m6A levels on known leukaemogenic mRNAs and a decrease in their expression consistent with a translational defect. We demonstrate that pharmacological inhibition of METTL3 in vivo leads to impaired engraftment and prolonged survival in various mouse models of AML, specifically targeting key stem cell subpopulations of AML. Collectively, these results reveal the inhibition of METTL3 as a potential therapeutic strategy against AML, and provide proof of concept that the targeting of RNA-modifying enzymes represents a promising avenue for anticancer therapy.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33902106",
          "offsetInBeginSection": 358,
          "offsetInEndSection": 1306
        }
      ],
      "id": "620c28d03a8413c653000007",
      "type": "factoid",
      "body": "Which type of cancer has been suggested as a strategy for potential small-molecule inhibition of METTL3?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32613381",
        "http://www.ncbi.nlm.nih.gov/pubmed/34488870",
        "http://www.ncbi.nlm.nih.gov/pubmed/33278455"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "These cell systems were then used to evaluate the anti-NASH properties of eight peroxisome proliferator-activated receptor (PPAR) agonists (bezafibrate, elafibranor, fenofibrate, lanifibranor, pemafibrate, pioglitazone, rosiglitazone, and saroglitazar).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32613381",
          "offsetInBeginSection": 683,
          "offsetInEndSection": 936
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34488870",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We have examined peroxisome proliferator-activated receptor (PPAR) pathway perturbation in this model and explored the impact of the pan-PPAR agonist lanifibranor on the cardiorespiratory phenotype.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34488870",
          "offsetInBeginSection": 210,
          "offsetInEndSection": 408
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33278455",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Given the current lack of an effective treatment, we aimed to characterise the effects of the pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist lanifibranor in 2 preclinical models of ACLD, as well as in liver cells from patients with ACLD.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33278455",
          "offsetInBeginSection": 289,
          "offsetInEndSection": 545
        }
      ],
      "id": "61f5f580882a024a10000017",
      "type": "summary",
      "body": "What is the mechanism of action of Lanifibranor?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33419445",
        "http://www.ncbi.nlm.nih.gov/pubmed/32347039",
        "http://www.ncbi.nlm.nih.gov/pubmed/33515421",
        "http://www.ncbi.nlm.nih.gov/pubmed/34844098"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " Both CD10 and HOXA11 have been implicated in regulation of endometrial homeostasis.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34844098",
          "offsetInBeginSection": 487,
          "offsetInEndSection": 571
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Combined expression of HOXA11 and CD10 identifies endometriosis versus normal tissue and tumors.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34844098",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The combination of HOXA11 and CD10 expression profiles provides a useful tool to identify ectopic endometrial tissue and for distinguishing endometriosis from various types of gynecological malignancies and metastases.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34844098",
          "offsetInBeginSection": 1347,
          "offsetInEndSection": 1565
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Downregulation of HOXA11 enhances endometrial cancer malignancy",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33515421",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 63
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Low HOXA11 expression may promote the proliferation, migration, invasion of endometrial cancer cells, and increase their resistance to cisplatin through activating PTEN/AKT pathway.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33515421",
          "offsetInBeginSection": 1583,
          "offsetInEndSection": 1764
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Endometrial mRNA and protein expression levels of HOXA10 and HOXA11 were significantly lower in patients with AM than in control patients.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33419445",
          "offsetInBeginSection": 923,
          "offsetInEndSection": 1061
        }
      ],
      "id": "621b61833a8413c65300003e",
      "type": "yesno",
      "body": "Is the protein HOXA11 associated with endometrial disease?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33021960",
        "http://www.ncbi.nlm.nih.gov/pubmed/33857358",
        "http://www.ncbi.nlm.nih.gov/pubmed/34862880"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "DEAH-Box helicase 36 (DHX36), a member of the large DExD/H box helicase family, enzymatically unwinds both G4 DNA and G4 RNA",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34862880",
          "offsetInBeginSection": 286,
          "offsetInEndSection": 410
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "RNA helicases of the DEAH/RHA family form a large and conserved class of enzymes that remodel RNA protein complexes (RNPs) by translocating along the RNA.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33857358",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "DHX36 is a member of the DExD/H box helicase family, which comprises a large number of proteins involved in various cellular functions. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33021960",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " G4s are alternative nucleic acid structures, which influence many cellular pathways on a transcriptional and post-transcriptional level. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33021960",
          "offsetInBeginSection": 227,
          "offsetInEndSection": 365
        }
      ],
      "id": "6220cf383a8413c653000069",
      "type": "summary",
      "body": "Summarize the function of DEAH helicase DHX36 and its role in G-quadruplex-dependent processes."
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26892542",
        "http://www.ncbi.nlm.nih.gov/pubmed/26981420",
        "http://www.ncbi.nlm.nih.gov/pubmed/24575094",
        "http://www.ncbi.nlm.nih.gov/pubmed/22570637",
        "http://www.ncbi.nlm.nih.gov/pubmed/18542060",
        "http://www.ncbi.nlm.nih.gov/pubmed/18046414",
        "http://www.ncbi.nlm.nih.gov/pubmed/16822951",
        "http://www.ncbi.nlm.nih.gov/pubmed/16314846",
        "http://www.ncbi.nlm.nih.gov/pubmed/15955096",
        "http://www.ncbi.nlm.nih.gov/pubmed/12411495",
        "http://www.ncbi.nlm.nih.gov/pubmed/9696045",
        "http://www.ncbi.nlm.nih.gov/pubmed/9359867",
        "http://www.ncbi.nlm.nih.gov/pubmed/8276234"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We present evidence that YY1, a ubiquitously expressed DNA-binding protein, regulates the activity of the c-fos promoter primarily through an effect on DNA structure. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8276234",
          "offsetInBeginSection": 139,
          "offsetInEndSection": 306
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "the principal function of YY1 in this promoter is to bend DNA to regulate contact between other proteins. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8276234",
          "offsetInBeginSection": 837,
          "offsetInEndSection": 943
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "By using oligonucleotide competition and a specific antibody we demonstrated that the transcription factor YY1 is responsible for the formation of complex BIII. Also in this case, the transient expression of the YY1 cDNA in CHO cells resulted in an increased transcription from the FE65 minimal promoter. The absence of any co-operative effect when CHO cells were co-transfected with both YY1 and Pur alpha cDNA species suggests that two different transcription regulatory mechanisms could have a role in the regulation of the FE65 gene.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9359867",
          "offsetInBeginSection": 1166,
          "offsetInEndSection": 1703
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "c-Myc and the multifunctional transcriptional regulator YY1 have been shown previously to interact directly",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9696045",
          "offsetInBeginSection": 22,
          "offsetInEndSection": 129
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We demonstrate that YY1 is a potent inhibitor of c-Myc transforming activity",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9696045",
          "offsetInBeginSection": 324,
          "offsetInEndSection": 400
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Furthermore the transactivation domain of YY1 was not necessary suggesting that gene regulation by YY1, for example through DNA bending or displacement of regulators from DNA, could be the cause for the negative regulation of c-Myc",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9696045",
          "offsetInBeginSection": 563,
          "offsetInEndSection": 794
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We suggest that the ability of RYBP to mediate an interaction between E2F2 or E2F3 and YY1 is an important component of Cdc6 activation and provides a basis for specificity of E2F function.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12411495",
          "offsetInBeginSection": 882,
          "offsetInEndSection": 1071
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "In accordance with this result, when Sp1 or YY1 was overexpressed in keratinocytes, an obvious increase in ATP2C1 promoter activity was observed, which was in contrast with the case where a mutant promoter lacking the binding sites for Sp1 and YY1 was used as the reporter.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15955096",
          "offsetInBeginSection": 484,
          "offsetInEndSection": 757
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "These results indicate that Sp1 and YY1 transactivate the human ATP2C1 promoter via cis-enhancing elements and that incomplete upregulation of ATP2C1 transcription contributes to the keratinocyte-specific pathogenesis of HHD. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15955096",
          "offsetInBeginSection": 947,
          "offsetInEndSection": 1173
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The ubiquitous transcription factor Yin Yang 1 (YY1) is known to have a fundamental role in normal biologic processes such as embryogenesis, differentiation, replication, and cellular proliferation.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16314846",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "YY1 overexpression and/or activation is associated with unchecked cellular proliferation, resistance to apoptotic stimuli, tumorigenesis and metastatic potential.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16314846",
          "offsetInBeginSection": 1103,
          "offsetInEndSection": 1265
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "recent findings implicate YY1 in the regulation of tumor cell resistance to chemotherapeutics and immune-mediated apoptotic stimuli",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16314846",
          "offsetInBeginSection": 1775,
          "offsetInEndSection": 1906
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Molecular mechanisms that have been investigated include YY1-mediated downregulation of p53 activity, interference with poly-ADP-ribose polymerase, alteration in c-myc and nuclear factor-kappa B (NF-kappaB) expression, regulation of death genes and gene products, and differential YY1 binding in the presence of inflammatory mediators",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16314846",
          "offsetInBeginSection": 1430,
          "offsetInEndSection": 1764
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "YY1, in addition to its regulatory roles in normal biologic processes, may possess the potential to act as an initiator of tumorigenesis and may thus serve as both a diagnostic and prognostic tumor marker; furthermore, it may provide an effective target for antitumor chemotherapy and/or immunotherapy.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16314846",
          "offsetInBeginSection": 1985,
          "offsetInEndSection": 2287
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "YY1 is a transcription factor that can activate or repress transcription of a variety of genes and is involved in several developmental processes.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16822951",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Knockdown of YY1 caused a significant decrease in mitochondrial gene expression and in respiration, and YY1 was required for rapamycin-dependent repression of those genes.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18046414",
          "offsetInBeginSection": 996,
          "offsetInEndSection": 1167
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "These and other results suggest that in quiescent cells the C-terminal region of p300 provides corepressor function and facilitates the recruitment of p300 and HDAC3 to the YY1-binding site and represses the c-Myc promoter. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18542060",
          "offsetInBeginSection": 812,
          "offsetInEndSection": 1036
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Although YY1 is a ubiquitous transcription factor, YY1 interacts with M-MITF, the Waardenburg Syndrome IIA gene and a master transcriptional regulator of melanocytes.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22570637",
          "offsetInBeginSection": 357,
          "offsetInEndSection": 523
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Moreover, ChIP-seq identified genome-wide YY1 targets in the melanocyte lineage.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22570637",
          "offsetInBeginSection": 647,
          "offsetInEndSection": 727
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Our recent data show that YY1 is also required for CSR.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24575094",
          "offsetInBeginSection": 1105,
          "offsetInEndSection": 1160
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The large numbers of post-translational modifications that control YY1 functions are possible candidates for regulation.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24575094",
          "offsetInBeginSection": 1759,
          "offsetInEndSection": 1879
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Here we describe the discovery and functional annotation of Linc-YY1, a novel lincRNA originating from the promoter of the transcription factor (TF) Yin Yang 1 (YY1). ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26981420",
          "offsetInBeginSection": 66,
          "offsetInEndSection": 233
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "YY1 inhibits Smad3/4 binding to and chromatin remodelling of the Foxp3 locus. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26892542",
          "offsetInBeginSection": 601,
          "offsetInEndSection": 679
        }
      ],
      "id": "5fd3c4f4a43ad31278000003",
      "type": "summary",
      "body": "What is the function of the YY1 transcriptional regulator?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18158835"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "It was found that pomegranate juice consumption decreased total hepatic CYP content as well as the expression of CYP1A2 and CYP3A. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18158835",
          "offsetInBeginSection": 859,
          "offsetInEndSection": 990
        }
      ],
      "id": "620c01ae3a8413c653000005",
      "type": "list",
      "body": "Which CYP genes\u0027 expression is decreased at the in vivo level following pomegranate juice consumption?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33956058"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Advances in cancer genomics have revealed genomic classes of acute myeloid leukemia (AML) characterized by class-defining mutations, such as chimeric fusion genes or in genes such as NPM1, MLL, and CEBPA. These class-defining mutations frequently synergize with internal tandem duplications in FLT3 (FLT3-ITDs) to drive leukemogenesis. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33956058",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 336
        }
      ],
      "id": "62128a913a8413c653000017",
      "type": "list",
      "body": "Class-defining mutations in which genes drive FLT3-ITD-mutant AML?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34482771",
        "http://www.ncbi.nlm.nih.gov/pubmed/34613603",
        "http://www.ncbi.nlm.nih.gov/pubmed/34590859",
        "http://www.ncbi.nlm.nih.gov/pubmed/34479868",
        "http://www.ncbi.nlm.nih.gov/pubmed/34818478",
        "http://www.ncbi.nlm.nih.gov/pubmed/33945366",
        "http://www.ncbi.nlm.nih.gov/pubmed/33931436"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "AIM AND RESULTS: This article describes the main acquisitions of RCC management, including the advent of a new combo (pembrolizumab+lenvatinib) as first-line therapy, the confirmation of an OS advantage of ICI plus VEGFR-TKI combinations over sunitinib at longer follow-up, the persistent benefit from these combinations in particular subgroups (clear cell mRCC tumors with sarcomatoid differentiation), and possible new approaches in subsequent lines of therapy (including the HIF-2α inhibitor belzutifan)",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34482771",
          "offsetInBeginSection": 186,
          "offsetInEndSection": 692
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Belzutifan (Welireg™) is an oral small molecule inhibitor of hypoxia-inducible factor (HIF)-2α being developed by Peloton Therapeutics for the treatment of solid tumours, including renal cell carcinoma (RCC) with clear cell histology (ccRCC) and von Hippel-Lindau (VHL) disease-associated RCC. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34613603",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 294
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "A detailed mechanistic understanding of a benzylic photobromination en route to belzutifan (MK-6482, a small molecule for the treatment of renal cell carcinoma associated with von Hippel-Lindau syndrome) has been achieved using in situ LED-NMR spectroscopy in conjunction with kinetic analysis. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34590859",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 295
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34818478",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 65
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "CONCLUSIONS: Belzutifan was associated with predominantly grade 1 and 2 adverse events and showed activity in patients with renal cell carcinomas and non-renal cell carcinoma neoplasms associated with VHL disease. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34818478",
          "offsetInBeginSection": 1752,
          "offsetInEndSection": 1966
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The small-molecule HIF 2 alpha inhibitor MK-6482 (belzutifan) has demonstrated significant efficacy in VHL disease related renal cell carcinomas, hemangioblastomas, and pancreatic neuroendocrine tumors while demonstrating an acceptable safety profile.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33945366",
          "offsetInBeginSection": 621,
          "offsetInEndSection": 872
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "The HIF2α Inhibitor Belzutifan Shows Signs of Efficacy in Kidney Cancer.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33931436",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 72
        }
      ],
      "id": "61f5924e882a024a1000000e",
      "type": "list",
      "body": "Belzutifan has shown effectiveness for which diseases?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32601292",
        "http://www.ncbi.nlm.nih.gov/pubmed/34141135"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " These PUX proteins specifically associate with the nucleoskeleton underneath the INM and physically interact with CDC48 proteins to negatively regulate INM protein degradation in plants.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32601292",
          "offsetInBeginSection": 849,
          "offsetInEndSection": 1036
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": " plant UBX-containing (PUX) proteins",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34141135",
          "offsetInBeginSection": 47,
          "offsetInEndSection": 83
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The activity and targeting of CDC48 are controlled by adaptor proteins, of which the plant ubiquitin regulatory X (UBX) domain-containing (PUX) proteins constitute the largest family. Emerging knowledge on the structure and function of PUX proteins highlights that these proteins are versatile factors for plant homeostasis and adaptation that might inspire biotechnological applications.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34141135",
          "offsetInBeginSection": 425,
          "offsetInEndSection": 813
        }
      ],
      "id": "621b54f03a8413c65300003b",
      "type": "factoid",
      "body": "Where are the PUX proteins found?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24095986",
        "http://www.ncbi.nlm.nih.gov/pubmed/24754976",
        "http://www.ncbi.nlm.nih.gov/pubmed/25113439",
        "http://www.ncbi.nlm.nih.gov/pubmed/19816193"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The immunosuppressive effects of CD4+ CD25 high regulatory T cells (Tregs) interfere with antitumor immune responses in cancer patients.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19816193",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Alteration of regulatory T cells (Tregs) may contribute to ineffective suppression of proinflammatory cytokines in type 1 diabetes.AIM",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25113439",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 146
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Regulatory T cells (Tregs) suppress excessive immune responses in IRI",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24754976",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 179
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "CD4(+)CD25(+) regulatory T cells (Tregs) are negative regulators of the immune system that induce and maintain immune tolerance.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24095986",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128
        }
      ],
      "id": "621ed10f3a8413c653000062",
      "type": "yesno",
      "body": "Are Tregs CD4(+)CD25(+) regulatory T cells a positive regulator of the immune response?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28839111",
        "http://www.ncbi.nlm.nih.gov/pubmed/28978570",
        "http://www.ncbi.nlm.nih.gov/pubmed/27376235",
        "http://www.ncbi.nlm.nih.gov/pubmed/25955728",
        "http://www.ncbi.nlm.nih.gov/pubmed/26416749",
        "http://www.ncbi.nlm.nih.gov/pubmed/25547603",
        "http://www.ncbi.nlm.nih.gov/pubmed/25263550",
        "http://www.ncbi.nlm.nih.gov/pubmed/23582322",
        "http://www.ncbi.nlm.nih.gov/pubmed/23582323"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "BRD4 and Mediator were found to co-occupy thousands of enhancers associated with active genes.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23582323",
          "offsetInBeginSection": 355,
          "offsetInEndSection": 449
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Master transcription factors and mediator establish super-enhancers at key cell identity genes",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23582322",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Master transcription factors Oct4, Sox2, and Nanog bind enhancer elements and recruit Mediator to activate much of the gene expression program of pluripotent embryonic stem cells (ESCs).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23582322",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "These domains, which we call super-enhancers, consist of clusters of enhancers that are densely occupied by the master regulators and Mediator",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23582322",
          "offsetInBeginSection": 324,
          "offsetInEndSection": 466
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "BRD4 maintains transcription of core stem cell genes such as OCT4 and PRDM14 by occupying their super-enhancers (SEs), large clusters of regulatory elements, and recruiting to them Mediator and CDK9, the catalytic subunit of the positive transcription elongation factor b (P-TEFb), to allow Pol-II-dependent productive elongation.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25263550",
          "offsetInBeginSection": 510,
          "offsetInEndSection": 840
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The term \u0027super-enhancer\u0027 has been used to describe groups of putative enhancers in close genomic proximity with unusually high levels of Mediator binding, as measured by chromatin immunoprecipitation and sequencing (ChIP-seq).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25547603",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Mediator kinase inhibition further activates super-enhancer-associated genes in AML.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26416749",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Furthermore, the binding of SIM2 marks a particular sub-category of enhancers known as super-enhancers. These regions are characterized by typical DNA modifications and Mediator co-occupancy (MED1 and MED12). ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25955728",
          "offsetInBeginSection": 839,
          "offsetInEndSection": 1048
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Many genes determining cell identity are regulated by clusters of Mediator-bound enhancer elements collectively referred to as super-enhancers. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27376235",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "A number of studies have recently demonstrated that super-enhancers, which are large cluster of enhancers typically marked by a high level of acetylation of histone H3 lysine 27 and mediator bindings, are frequently associated with genes that control and define cell identity during normal development. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28978570",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 303
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Super-enhancers are characterized by high levels of Mediator binding and are major contributors to the expression of their associated genes. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28839111",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141
        }
      ],
      "id": "5fdb4100a43ad31278000015",
      "type": "yesno",
      "body": "Is Mediator present at super enhancers?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34881402"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Atemoya juice significantly inhibited CYP1A2 activity in human liver microsomes, but not the activities of CYP2C9 and CYP3A.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34881402",
          "offsetInBeginSection": 838,
          "offsetInEndSection": 962
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "This suggests that the intake of an excess amount of atemoya juice is necessary to cause a change in the pharmacokinetics of phenacetin when the IC50 values for CYP1A2 inhibition by atemoya and fluvoxamine are taken into account",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34881402",
          "offsetInBeginSection": 1263,
          "offsetInEndSection": 1491
        }
      ],
      "id": "62057b35c9dfcb9c0900002d",
      "type": "yesno",
      "body": "Does atemoya juice inhibit the CYP1A2 enzyme?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34626583"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Bi-allelic variants in SPATA5L1 lead to intellectual disability, spastic-dystonic cerebral palsy, epilepsy, and hearing loss.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34626583",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We report 28 bi-allelic variants in SPATA5L1 associated with sensorineural hearing loss in 47 individuals from 28 (26 unrelated) families. In addition, 25/47 affected individuals (53%) presented with microcephaly, developmental delay/intellectual disability, cerebral palsy, and/or epilepsy.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34626583",
          "offsetInBeginSection": 113,
          "offsetInEndSection": 404
        }
      ],
      "id": "620997e9c9dfcb9c09000042",
      "type": "list",
      "body": "What is caused by biallelic variants in SPATA5L1?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32349374",
        "http://www.ncbi.nlm.nih.gov/pubmed/32984090",
        "http://www.ncbi.nlm.nih.gov/pubmed/33139264",
        "http://www.ncbi.nlm.nih.gov/pubmed/33213161"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "A successful phase III trial for the combination of atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32349374",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "ndeed, preliminary results from phase I studies of lenvatinib plus pembrolizumab and atezolizumab plus bevacizumab have proved favorable, prompting phase III investigations in the frontline setting, and for atezolizumab plus bevacizumab, these positive findings have been substantiated by recent reporting of phase III data from IMbrave150.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32984090",
          "offsetInBeginSection": 1120,
          "offsetInEndSection": 1460
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The approval was based on data from Study IMbrave150, which randomly allocated (2:1) patients to receive either atezolizumab plus bevacizumab (atezolizumab-bevacizumab) or sorafenib. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33139264",
          "offsetInBeginSection": 238,
          "offsetInEndSection": 421
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "In study IMbrave150, the combination of atezolizumab and bevacizumab was successfully used compared to sorafenib in the first-line treatment.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33213161",
          "offsetInBeginSection": 1993,
          "offsetInEndSection": 2134
        }
      ],
      "id": "602346eb1cb411341a000090",
      "type": "list",
      "body": "A combination of which two drugs was tested in the IMbrave150 trial?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34587215",
        "http://www.ncbi.nlm.nih.gov/pubmed/33027627",
        "http://www.ncbi.nlm.nih.gov/pubmed/34025336",
        "http://www.ncbi.nlm.nih.gov/pubmed/32391572",
        "http://www.ncbi.nlm.nih.gov/pubmed/31959876"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Amyotrophic lateral sclerosis (ALS) is the most frequent adult-onset motor neuron disorder. The disease is characterized by degeneration of upper and lower motor neurons, leading to death usually within five years after the onset of symptoms. While most cases are sporadic, 5%-10% of cases can be associated with familial inheritance, including ALS type 6, which is associated with mutations in the Fused in Sarcoma (FUS) gene.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34587215",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 427
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder of the motor system. The etiology is still unknown and the pathogenesis remains unclear. ALS is familial in the 10% of cases with a Mendelian pattern of inheritance.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33027627",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 245
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Amyotrophic lateral sclerosis (ALS) is a severe disease causing motor neuron death, but a complete cure has not been developed and related genes have not been defined in more than 80% of cases. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31959876",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. The majority of cases are sporadic (sALS), while the most common inherited form is due to C9orf72 mutation (C9ALS).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32391572",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "At least 30 genes have been implicated in familial ALS (fALS) and sporadic ALS (sALS). ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34025336",
          "offsetInBeginSection": 181,
          "offsetInEndSection": 268
        }
      ],
      "id": "6217dba43a8413c653000029",
      "type": "summary",
      "body": "Is ALS a heritable disease?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28251886"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Long noncoding RNA (lncRNA) antisense noncoding RNA in the INK4 locus (ANRIL) is involved in several human cancers. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28251886",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116
        }
      ],
      "id": "62211fdf3a8413c653000073",
      "type": "summary",
      "body": "What is ARNIL?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34256819"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "CPX-351 (United States: Vyxeos®; Europe: Vyxeos® Liposomal), a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, is approved by the US FDA and the EMA for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34256819",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 362
        }
      ],
      "id": "6211575f3a8413c653000011",
      "type": "summary",
      "body": "What is the indication of CPX-351?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34172899"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Biallelic variants in KARS1 are associated with neurodevelopmental disorders and hearing loss recapitulated by the knockout zebrafish.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34172899",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Pathogenic variants in Lysyl-tRNA synthetase 1 (KARS1) have increasingly been recognized as a cause of early-onset complex neurological phenotypes. To advance the timely diagnosis of KARS1-related disorders, we sought to delineate its phenotype and generate a disease model to understand its function in vivo.METHODS: Through international collaboration, we identified 22 affected individuals from 16 unrelated families harboring biallelic likely pathogenic or pathogenic in KARS1 variants. Sequencing approaches ranged from disease-specific panels to genome sequencing. We generated loss-of-function alleles in zebrafish.RESULTS: We identify ten new and four known biallelic missense variants in KARS1 presenting with a moderate-to-severe developmental delay, progressive neurological and neurosensory abnormalities, and variable white matter involvement. We describe novel KARS1-associated signs such as autism, hyperactive behavior, pontine hypoplasia, and cerebellar atrophy with prevalent vermian involvement. Loss of kars1 leads to upregulation of p53, tissue-specific apoptosis, and downregulation of neurodevelopmental related genes, recapitulating key tissue-specific disease phenotypes of patients.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34172899",
          "offsetInBeginSection": 9,
          "offsetInEndSection": 1217
        }
      ],
      "id": "61f808cd882a024a1000003a",
      "type": "list",
      "body": "List signs of patients with biallelic variants in KARS1"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32659068",
        "http://www.ncbi.nlm.nih.gov/pubmed/32300441"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Brodifacoum Poisoning Linked to Synthetic Marijuana Use in Wisconsin.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32659068",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 69
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "INTRODUCTION: Recent outbreaks of brodifacoum-induced coagulopathy resulting from the use of synthetic cannabinoids represents a growing public health concern. Brodifacoum is a commonly used and commercially available rodenticide that has anticoagulant properties. As new, unregulated synthetic cannabinoids enter the market, the potential for further outbreaks continues to rise.CASE PRESENTATION: We report a case of severe bleeding secondary to inhalation of synthetic cannabinoids contaminated with brodifacoum. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32659068",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 516
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "CONCLUSION: While hemorrhaging after exposure to synthetic cannabinoids has been reported previously, we use this case to increase awareness of the potentially deadly exposures to brodifacoum from synthetic cannabinoids use in Wisconsin. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32659068",
          "offsetInBeginSection": 933,
          "offsetInEndSection": 1171
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Disseminated Intravascular Coagulopathy Secondary to Unintentional Brodifacoum Poisoning via Synthetic Marijuana.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32300441",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Recent evidence demonstrates a rising epidemic of unintentional brodifacoum poisoning associated with synthetic cannabinoid use.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32300441",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We present a rare case of severe coagulopathy and cardiac arrest secondary to synthetic cannabinoid use complicated by brodifacoum toxicity.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32300441",
          "offsetInBeginSection": 247,
          "offsetInEndSection": 387
        }
      ],
      "id": "6024a6871cb411341a0000a4",
      "type": "factoid",
      "body": "Which substance use is associated with Brodifacoum poisoning?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34469019",
        "http://www.ncbi.nlm.nih.gov/pubmed/34586808",
        "http://www.ncbi.nlm.nih.gov/pubmed/34265844"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Highly accurate protein structure prediction with AlphaFold.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34265844",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 60
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "AlphaFold is a novel machine learning approach that incorporates physical and biological knowledge about protein structure, leveraging multi-sequence alignments, into the design of the deep learning algorithm.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34265844",
          "offsetInBeginSection": 1469,
          "offsetInEndSection": 1678
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Using novel deep learning, AF2 predicted the structures of many difficult protein targets at or near experimental resolution.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34586808",
          "offsetInBeginSection": 93,
          "offsetInEndSection": 218
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " Using the neural network-based method AlphaFold2, 3D structures of almost the entire human proteome have been predicted and made available (https://www.alphafold.ebi.ac.uk).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34469019",
          "offsetInBeginSection": 150,
          "offsetInEndSection": 324
        }
      ],
      "id": "621b4a223a8413c65300003a",
      "type": "factoid",
      "body": "What is Alphafold?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34502075",
        "http://www.ncbi.nlm.nih.gov/pubmed/32695777"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Fragile X-related disorders (FXDs), also known as FMR1 disorders, are examples of repeat expansion diseases (REDs), clinical conditions that arise from an increase in the number of repeats in a disease-specific microsatellite. I",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34502075",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "he Fragile-X related disorders (FXDs) are Repeat Expansion Diseases (REDs) that result from expansion of a CGG-repeat tract located at the 5\u0027 end of the FMR1 gene. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32695777",
          "offsetInBeginSection": 1,
          "offsetInEndSection": 165
        }
      ],
      "id": "621fc8513a8413c653000063",
      "type": "list",
      "body": "List diseases that are  repeat expansion disorders (REDs)."
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32055000",
        "http://www.ncbi.nlm.nih.gov/pubmed/34256819"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Here, we review three common treatment modalities used to target BCMA in the treatment of MM: bispecific antibody constructs, antibody-drug conjugates, and chimeric antigen receptor (CAR)-modified T-cell therapy. We provide an overview of preliminary clinical data from trials using these therapies, including the BiTE® (bispecific T-cell engager) immuno-oncology therapy AMG 420, the antibody-drug conjugate GSK2857916, and several CAR T-cell therapeutic agents including bb2121, NIH CAR-BCMA, and LCAR-B38M. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32055000",
          "offsetInBeginSection": 1074,
          "offsetInEndSection": 1584
        }
      ],
      "id": "621150333a8413c65300000e",
      "type": "summary",
      "body": "What is bb21217?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33970200"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Biallelic variants in HPDL cause pure and complicated hereditary spastic paraplegia.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33970200",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Our findings suggest that biallelic HPDL variants cause a syndrome varying from juvenile-onset pure hereditary spastic paraplegia to infantile-onset spastic tetraplegia associated with global developmental delays.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33970200",
          "offsetInBeginSection": 1424,
          "offsetInEndSection": 1637
        }
      ],
      "id": "61f81785882a024a1000003f",
      "type": "summary",
      "body": "Describe the syndrome that is caused by biallelic variants in HPDL"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33785490",
        "http://www.ncbi.nlm.nih.gov/pubmed/33661508",
        "http://www.ncbi.nlm.nih.gov/pubmed/34085329",
        "http://www.ncbi.nlm.nih.gov/pubmed/33919434",
        "http://www.ncbi.nlm.nih.gov/pubmed/34678325",
        "http://www.ncbi.nlm.nih.gov/pubmed/34626330"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "A prior Phase I proof-of-concept study showed rapid improvements in skin and pustule clearance with a single intravenous dose of spesolimab, a novel anti-interleukin-36 receptor antibody, in patients presenting with an acute GPP flare.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33785490",
          "offsetInBeginSection": 536,
          "offsetInEndSection": 771
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The objectives of this study were to evaluate the safety and efficacy of spesolimab, a novel anti-interleukin-36 receptor antibody, in patients with PPP.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33661508",
          "offsetInBeginSection": 226,
          "offsetInEndSection": 379
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Directing treatment at neutrophil recruitment and activation by targeting IL-36 with spesolimab fits well in the pathogenic concept of HS and clinical phase II trial results are pending.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34085329",
          "offsetInBeginSection": 1049,
          "offsetInEndSection": 1235
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Two IL-36R blocking antibodies, imsidolimab and spesolimab, are currently undergoing phase II and III clinical trials, with promising results.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33919434",
          "offsetInBeginSection": 343,
          "offsetInEndSection": 485
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " In a proof-of-concept clinical trial, treatment with spesolimab, an anti-IL-36 receptor antibody, resulted in rapid skin and pustular clearance in patients presenting with GPP flares.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34678325",
          "offsetInBeginSection": 107,
          "offsetInEndSection": 291
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Recently, specific inhibitors of the IL-36 pathway have been evaluated in GPP and PPP, including spesolimab, an IL-36 receptor inhibitor which has shown promising results in GPP. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34626330",
          "offsetInBeginSection": 1679,
          "offsetInEndSection": 1858
        }
      ],
      "id": "61f5847b882a024a10000008",
      "type": "factoid",
      "body": "Which receptor is targeted by Spesolimab?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34375485",
        "http://www.ncbi.nlm.nih.gov/pubmed/32306372",
        "http://www.ncbi.nlm.nih.gov/pubmed/34556565",
        "http://www.ncbi.nlm.nih.gov/pubmed/34519102",
        "http://www.ncbi.nlm.nih.gov/pubmed/34480363"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Neurofilament light chain (NfL) has recently been proposed as a promising biomarker in frontotemporal dementia (FTD). ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34375485",
          "offsetInBeginSection": 24,
          "offsetInEndSection": 142
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Neurofilament light chain (NfL) is a new, non-disease specific, widely studied biomarker indicative of axonal injury and degeneration",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32306372",
          "offsetInBeginSection": 227,
          "offsetInEndSection": 360
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "the neurodegeneration biomarker neurofilament light chain (NfL) ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34556565",
          "offsetInBeginSection": 709,
          "offsetInEndSection": 773
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "bNfL can be used as a potential biomarker to predict disease onset, severity, and progression of genetic ataxia.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34519102",
          "offsetInBeginSection": 1408,
          "offsetInEndSection": 1520
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Neurofilament light chain protein (NfL) is a promising biomarker of neurodegeneration.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34480363",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 98
        }
      ],
      "id": "6217dc9d3a8413c65300002d",
      "type": "yesno",
      "body": "Is NfL (neurofilament light chain) a biomarker of neurodegeneration?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30719578",
        "http://www.ncbi.nlm.nih.gov/pubmed/24155599"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " The overall survival rate of the implants into the sinus cavity was 95.6%, without statistical differences according to the level of penetration. The clinical and radiological complications were 3.4% and 14.8% respectively. The most frequent clinical complication was the epistaxis, ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30719578",
          "offsetInBeginSection": 2399,
          "offsetInEndSection": 2683
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "implant placement and protrusion of the implant up to 3mm beyond the sinus floor does not alter the stability and outcome of dental implants, one year post-restoration. This could be associated with minor complications ranging from epistaxis to sinusitis, which are manageable.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24155599",
          "offsetInBeginSection": 1075,
          "offsetInEndSection": 1352
        }
      ],
      "id": "621ebec63a8413c65300005d",
      "type": "yesno",
      "body": "Is Epistaxis associated with dental implant placement?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31828807"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The inhibition of CYP3A by grapefruit juice was significantly attenuated by processing particularly with γCD.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31828807",
          "offsetInBeginSection": 886,
          "offsetInEndSection": 995
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The encapsulation of BG and DHBG by γCD and the resulting attenuation of the inhibition of CYP3A activity by grapefruit juice may be applicable to juice processing for preventing drug-grapefruit juice interactions.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31828807",
          "offsetInBeginSection": 1175,
          "offsetInEndSection": 1389
        }
      ],
      "id": "62058198c9dfcb9c09000030",
      "type": "factoid",
      "body": "What is the effect of grapefruit juice on CYP3A4?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33938912"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "FDXR-associated disease is a phenotypically heterogeneous disorder with retinal dystrophy being a major clinical feature observed in this cohort. In addition, we hypothesize that a number of factors are likely to drive the pathogenesis of optic atrophy, retinal degeneration, and perhaps the associated systemic manifestations.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33938912",
          "offsetInBeginSection": 1204,
          "offsetInEndSection": 1531
        }
      ],
      "id": "61f81857882a024a10000040",
      "type": "factoid",
      "body": "Which is the major clinical feature observed in FDXR-associated disease?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33561857",
        "http://www.ncbi.nlm.nih.gov/pubmed/33744933",
        "http://www.ncbi.nlm.nih.gov/pubmed/33628028",
        "http://www.ncbi.nlm.nih.gov/pubmed/33964183",
        "http://www.ncbi.nlm.nih.gov/pubmed/34713596",
        "http://www.ncbi.nlm.nih.gov/pubmed/34739196",
        "http://www.ncbi.nlm.nih.gov/pubmed/34739194"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "CONCLUSIONS: Oral daprodustat was noninferior to CERA in achieving and maintaining target hemoglobin levels in Japanese ND patients. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33561857",
          "offsetInBeginSection": 1989,
          "offsetInEndSection": 2122
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "BACKGROUND: The Anemia Studies in chronic kidney disease (CKD): Erythropoiesis via a Novel prolyl hydroxylase inhibitor (PHI) Daprodustat-Dialysis (ASCEND-D) trial will test the hypothesis that daprodustat is non-inferior to comparator epoetin alfa or darbepoetin alfa for two co-primary endpoints: haemoglobin efficacy and cardiovascular safety.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33744933",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 346
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Daprodustat is one of the orally administrated small-molecule HIF-PH inhibitors, leading to an increase in erythropoietin production, which is regulated by HIF. Also, daprodustat is expected to improve iron metabolism. Recently, several clinical trials showed its efficacy and safety in both hemodialysis- and non-hemodialysis- dependent CKD patients. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33628028",
          "offsetInBeginSection": 397,
          "offsetInEndSection": 749
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Once-daily oral daprodustat treatment was generally well tolerated and mean hemoglobin was achieved and maintained within the target range in Japanese peritoneal dialysis participants.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33964183",
          "offsetInBeginSection": 819,
          "offsetInEndSection": 1003
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Daprodustat is a hypoxia-inducible factor-prolyl hydroxylase inhibitor for the treatment of anemia of chronic kidney disease. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33964183",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is being investigated for treatment of anemia in chronic kidney disease.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34713596",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34739196",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 76
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "ONCLUSIONS: Among patients with CKD and anemia who were not undergoing dialysis, daprodustat was noninferior to darbepoetin alfa with respect to the change in the hemoglobin level from baseline and with respect to cardiovascular outcomes. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34739196",
          "offsetInBeginSection": 1701,
          "offsetInEndSection": 1940
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34739194",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 72
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "CONCLUSIONS: Among patients with CKD undergoing dialysis, daprodustat was noninferior to ESAs regarding the change in the hemoglobin level from baseline and cardiovascular outcomes.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34739194",
          "offsetInBeginSection": 2021,
          "offsetInEndSection": 2202
        }
      ],
      "id": "61f58a1a882a024a10000009",
      "type": "yesno",
      "body": "Is Daprodustat effective for anemia?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33467515",
        "http://www.ncbi.nlm.nih.gov/pubmed/33410220",
        "http://www.ncbi.nlm.nih.gov/pubmed/33710487",
        "http://www.ncbi.nlm.nih.gov/pubmed/33884612"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " a family of pore-forming proteins (PFPs), known as perforin like proteins (PLPs)",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33467515",
          "offsetInBeginSection": 139,
          "offsetInEndSection": 220
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "cytotoxic granules (granzyme B, granulysin, and perforin)",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33410220",
          "offsetInBeginSection": 943,
          "offsetInEndSection": 1000
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Granzyme B and perforin are stored inside the leukocytes in secretory granules.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33710487",
          "offsetInBeginSection": 355,
          "offsetInEndSection": 434
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "T cells produce effector molecules that are either directly cytotoxic, such as granzymes, perforin",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33884612",
          "offsetInBeginSection": 162,
          "offsetInEndSection": 260
        }
      ],
      "id": "6217da133a8413c653000026",
      "type": "factoid",
      "body": "Where is the the protein perforin localized?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27645815",
        "http://www.ncbi.nlm.nih.gov/pubmed/22648975",
        "http://www.ncbi.nlm.nih.gov/pubmed/22982408",
        "http://www.ncbi.nlm.nih.gov/pubmed/24095986",
        "http://www.ncbi.nlm.nih.gov/pubmed/28446531"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "All known cells continuously release nanoscale lipid membrane-enclosed packets. These packets, termed extracellular vesicles (EVs), bear the signature of their cells of origin. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27645815",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Exosomes are a type of cell-derived extracellular nanovesicle.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22648975",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 62
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Exosomes are small extracellular vesicles released to the extracellular milieu through fusion of multivesicular bodies with the plasma membrane.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22982408",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Exosomes are natural products released from many sources and play a role in antigen presentation, immunoregulation, and signal transduction.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24095986",
          "offsetInBeginSection": 129,
          "offsetInEndSection": 269
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " Exosomes, cell-derived vesicles encompassing lipids, DNA, proteins coding genes and noncoding RNAs (ncRNAs) are present in diverse body fluids.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28446531",
          "offsetInBeginSection": 11,
          "offsetInEndSection": 155
        }
      ],
      "id": "621ecf1a3a8413c653000061",
      "type": "factoid",
      "body": "What is an exosome?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33651100"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "CD3-engaging bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T cells are potent therapeutic approaches for redirecting patient T cells to recognize and kill tumors. Here we describe a fully human bsAb (REGN5458) that binds to B-cell maturation antigen (BCMA) and CD3, and compare its antitumor activities vs those of anti-BCMA CAR T cells to identify differences in efficacy and mechanism of action. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33651100",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 418
        }
      ],
      "id": "621218353a8413c653000013",
      "type": "yesno",
      "body": "Is REGN5458 a single-targeted antibody?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34413140"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34413140",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Overall, X-linked recessive TLR7 deficiency is a highly penetrant genetic etiology of critical COVID-19 pneumonia, in about 1.8% of male patients below the age of 60 years. Human TLR7 and pDCs are essential for protective type I IFN immunity against SARS-CoV-2 in the respiratory tract.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34413140",
          "offsetInBeginSection": 1352,
          "offsetInEndSection": 1638
        }
      ],
      "id": "62190bac3a8413c653000034",
      "type": "factoid",
      "body": "Which disease is associated with X-linked recessive TLR7 deficiency?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32224275",
        "http://www.ncbi.nlm.nih.gov/pubmed/30015639"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Finally, treatments aimed at reducing eosinophil accumulation and activation, such as the anti-IL-5 antibodies mepolizumab, reslizumab, and benralizumab, have been reported to reduce CSU symptoms. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32224275",
          "offsetInBeginSection": 1038,
          "offsetInEndSection": 1235
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The treatments that are under clinical trials for CSU are anti-IgE treatments such as ligelizumab, molecules targeting intracellular signaling pathways such as spleen tyrosine kinase inhibitors, surface inhibitory molecules such as siglec-8, anti-IL-1s such as canakinumab, Bruton kinase (BTK) inhibitors such as GDC-0853 and anti-IL-5s such as benralizumab and mepolizumab.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30015639",
          "offsetInBeginSection": 789,
          "offsetInEndSection": 1163
        }
      ],
      "id": "6020a7391cb411341a00007e",
      "type": "yesno",
      "body": "Is Benralizumab effective for Chronic Spontaneous Urticaria?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34433061"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "we show that Amot binds Talin and is essential for relaying forces between fibronectin and the cytoskeleton",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34433061",
          "offsetInBeginSection": 652,
          "offsetInEndSection": 759
        }
      ],
      "id": "6217dd013a8413c65300002f",
      "type": "yesno",
      "body": "Do the proteins Talin and Amot interact?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25483082"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " We investigated 2 mRNA-binding proteins - HuR and TIAR showing specificity to AU-Rich Element (ARE) sites in 3\u0027UTR of mRNA.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25483082",
          "offsetInBeginSection": 554,
          "offsetInEndSection": 678
        }
      ],
      "id": "6220cbf83a8413c653000067",
      "type": "yesno",
      "body": "Do RNA binding Proteins  that bind to adenine uridine (AU)-rich elements (AREs) in the 5\u0027 untranslated region (UTR) of mRNAs (AU-RBPs) regulate the DNA Damage Response?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34256819"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "CPX-351 (United States: Vyxeos®; Europe: Vyxeos® Liposomal), a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, is approved by the US FDA and the EMA for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34256819",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 362
        }
      ],
      "id": "6211566a3a8413c653000010",
      "type": "yesno",
      "body": "Has CPX-351 been approved by the FDA and the EMA?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32764680"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32764680",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " Here we investigate the essentiality of lysine acetyltransferase KAT7 in AMLs driven by the MLL-X gene fusions. We found that KAT7 loss leads to a rapid and complete loss of both H3K14ac and H4K12ac marks, in association with reduced proliferation, increased apoptosis, and differentiation of AML cells. Acetyltransferase activity of KAT7 is essential for the proliferation of these cells. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32764680",
          "offsetInBeginSection": 449,
          "offsetInEndSection": 840
        }
      ],
      "id": "620c2d743a8413c653000008",
      "type": "summary",
      "body": "What is the role of KAT7 in AML?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32703200",
        "http://www.ncbi.nlm.nih.gov/pubmed/33270098",
        "http://www.ncbi.nlm.nih.gov/pubmed/31144145",
        "http://www.ncbi.nlm.nih.gov/pubmed/30049885",
        "http://www.ncbi.nlm.nih.gov/pubmed/28968978",
        "http://www.ncbi.nlm.nih.gov/pubmed/27121793",
        "http://www.ncbi.nlm.nih.gov/pubmed/26632033"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "AXEPT, an Asian phase III study, showed that modified CAPIRI+BEV [capecitabine (CAP: 1600 mg/m2), irinotecan (IRI: 200 mg/m2), and BEV (7.5 mg/m2)] was non-inferior to FOLFIRI+BEV as a second-line therapy for mCRC patients and was associated with a lower incidence of hematologic toxicities. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32703200",
          "offsetInBeginSection": 263,
          "offsetInEndSection": 555
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Objective: To compare the efficacy of capecitabine plus irinotecan (CAPIRI) vs irinotecan (IRI) alone in patients with advanced gallbladder cancer (GBC) who have disease progression after gemcitabine-based first-line treatment.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33270098",
          "offsetInBeginSection": 221,
          "offsetInEndSection": 448
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "BACKGROUND: Triweekly capecitabine plus irinotecan (CAPIRI) was not a replacement for fluorouracil, leucovorin, and irinotecan (FOLFIRI) in the treatment of metastatic colorectal cancer (mCRC) because of the potential for greater toxicity. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31144145",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "PURPOSE: The aim of this randomized, multicenter, noncomparative, phase II trial was to investigate the efficacy and safety of two potential first-line treatments, capecitabine and oxaliplatin (CapOX) plus bevacizumab (BEV) and capecitabine and irinotecan (CapIRI) plus bevacizumab, in Japanese patients with metastatic colorectal cancer (mCRC).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30049885",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 345
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "A large series of samples (n\u003d818) from two phase III clinical trials was used to evaluate these candidate genes by correlating methylation status to progression-free survival after treatment with first-line single-agent fluorouracil (Capecitabine or 5-fluorouracil) or combination chemotherapy (Capecitabine or 5-fluorouracil plus irinotecan (CAPIRI/FOLFIRI)).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968978",
          "offsetInBeginSection": 408,
          "offsetInEndSection": 768
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Among these patients, 90 received capecitabine monotherapy as first-line therapy, and 93 received capecitabine plus irinotecan (CAPIRI) therapy as part of the CAIRO phase III clinical trial.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27121793",
          "offsetInBeginSection": 773,
          "offsetInEndSection": 963
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "A nonrandomized phase 1 dose-escalation study of ABT-751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab was conducted to define the maximum tolerated dose, dose-limiting toxicity (DLT), and pharmacokinetics in patients with advanced colorectal cancer. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26632033",
          "offsetInBeginSection": 75,
          "offsetInEndSection": 353
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26632033",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141
        }
      ],
      "id": "6027549d1cb411341a0000ea",
      "type": "list",
      "body": "Which drugs are included in the CAPIRI regimen?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33137401",
        "http://www.ncbi.nlm.nih.gov/pubmed/33594055",
        "http://www.ncbi.nlm.nih.gov/pubmed/33715349"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "crAssphages are a broad group of diverse bacteriophages in the order Caudovirales that have been found to be highly abundant in the human gastrointestinal tract. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33137401",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "CrAssphage is the most abundant human-associated virus and the founding member of a large group of bacteriophages, discovered in animal-associated and environmental metagenomes, that infect bacteria of the phylum Bacteroidetes. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33594055",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " crAssphage has been proposed as a human-specific marker for tracking fecal contamination. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33715349",
          "offsetInBeginSection": 9,
          "offsetInEndSection": 100
        }
      ],
      "id": "621b45943a8413c653000039",
      "type": "summary",
      "body": "What is the p-crAssphage?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34100450",
        "http://www.ncbi.nlm.nih.gov/pubmed/34699790",
        "http://www.ncbi.nlm.nih.gov/pubmed/31897908",
        "http://www.ncbi.nlm.nih.gov/pubmed/31998941",
        "http://www.ncbi.nlm.nih.gov/pubmed/32667692"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Circular RNAs (circRNAs) are a class of conserved, endogenous non-coding RNAs that are involved in transcriptional and post-transcriptional gene regulation ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34100450",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Circular RNAs (circRNAs) are important for the development and regeneration of the nervous system. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34699790",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Circular RNAs (circRNAs) are a type of single-stranded RNA molecules that normally do not encode proteins. circRNAs are involved in many physiological processes as well as the pathogenesis of diseases.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31897908",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Circular RNAs (circRNAs) are covalently closed RNA molecules that have been linked to various diseases, including cancer.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31998941",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Circular RNAs (circRNA) have been reported as regulators involved in hepatocellular carcinoma (HCC), but their mechanism of activity remains unknown.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32667692",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149
        }
      ],
      "id": "62211ce03a8413c65300006e",
      "type": "summary",
      "body": "What is the function of Circular RNA (circRNA)?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24925412"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The first chromone in clinical use, khellin, was extracted from the seeds of the plant Ammi visnaga, and had been used for centuries as a diuretic and as a smooth muscle relaxant. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24925412",
          "offsetInBeginSection": 142,
          "offsetInEndSection": 322
        }
      ],
      "id": "6206cfd5c9dfcb9c09000040",
      "type": "factoid",
      "body": "Which one was the first chromone in clinical use?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29335563"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Visualization and analysis of non-covalent contacts using the Protein Contacts Atlas.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29335563",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We present the Protein Contacts Atlas, an interactive resource of non-covalent contacts from over 100,000 PDB crystal structures. We developed multiple representations for visualization and analysis of non-covalent contacts at different scales of organization: atoms, residues, secondary structure, subunits, and entire complexes. The Protein Contacts Atlas enables researchers from different disciplines to investigate diverse questions in the framework of non-covalent contacts, including the interpretation of allostery, disease mutations and polymorphisms, by exploring individual subunits, interfaces, and protein-ligand contacts and by mapping external information. The Protein Contacts Atlas is available at http://www.mrc-lmb.cam.ac.uk/pca/ and also through PDBe.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29335563",
          "offsetInBeginSection": 381,
          "offsetInEndSection": 1152
        }
      ],
      "id": "605fb19794d57fd879000038",
      "type": "factoid",
      "body": "Which resource is used for visualisation of non-covalent contacts?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32447592",
        "http://www.ncbi.nlm.nih.gov/pubmed/32374962",
        "http://www.ncbi.nlm.nih.gov/pubmed/32648854"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "All patients who received the complement blocker eculizumab in addition to the interferon gamma blocker emapalumab had complete resolution of their TMA and survived. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32447592",
          "offsetInBeginSection": 1117,
          "offsetInEndSection": 1283
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32374962",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 71
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "CONCLUSIONS: Emapalumab was an efficacious targeted therapy for patients with primary hemophagocytic lymphohistiocytosis. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32374962",
          "offsetInBeginSection": 2045,
          "offsetInEndSection": 2167
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Emapalumab for the treatment of hemophagocytic lymphohistiocytosis.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32648854",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 67
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Emapalumab-Igsz (Gamifant) is a human monoclonal antibody directed against interferon-γ (IFN-γ), and the first Food and Drug Administration (FDA)-approved therapy for primary hemophagocytic lymphohistiocytosis (HLH).",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32648854",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Emapalumab is approved for treatment of primary HLH that is refractory, recurrent, progressing or intolerant to current HLH treatments in both adult and pediatric patients. FDA approval was based on the results of a phase II/III clinical trial evaluating the safety and efficacy of emapalumab in 34 pediatric patients with primary HLH, 27 of whom were refractory to current therapies. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32648854",
          "offsetInBeginSection": 424,
          "offsetInEndSection": 809
        }
      ],
      "id": "60234dc61cb411341a000094",
      "type": "factoid",
      "body": "Which disease is treated with Emapalumab?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34560321",
        "http://www.ncbi.nlm.nih.gov/pubmed/33465423",
        "http://www.ncbi.nlm.nih.gov/pubmed/33176253",
        "http://www.ncbi.nlm.nih.gov/pubmed/33171009",
        "http://www.ncbi.nlm.nih.gov/pubmed/33137401"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "a multitude of symbiotic bacteria and bacteriophages are decreased in abundance in patients with COVID-19",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34560321",
          "offsetInBeginSection": 830,
          "offsetInEndSection": 935
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Bacterial viruses (bacteriophages, phages) of the gut have increasingly become a focus in microbiome studies, with an understanding that they are likely key players in health and disease.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33465423",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Already without exogenous intervention, a multitude of phage-bacterial interactions occur within the human gut, some of which might play a direct role in disease progression",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33176253",
          "offsetInBeginSection": 286,
          "offsetInEndSection": 459
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We are surrounded by microbes, mostly bacteria and their viruses or phages, on the inside and outside of our bodies. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33171009",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "crAssphages are a broad group of diverse bacteriophages in the order Caudovirales that have been found to be highly abundant in the human gastrointestinal tract. Despite their high prevalence, we have an incomplete understanding of how crAssphages shape and respond to ecological and evolutionary dynamics in the gut.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33137401",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 317
        }
      ],
      "id": "6217dc173a8413c65300002b",
      "type": "yesno",
      "body": "Do we find bacteriophages in the gut?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34541851",
        "http://www.ncbi.nlm.nih.gov/pubmed/32437472",
        "http://www.ncbi.nlm.nih.gov/pubmed/29490074",
        "http://www.ncbi.nlm.nih.gov/pubmed/25896760",
        "http://www.ncbi.nlm.nih.gov/pubmed/30289101",
        "http://www.ncbi.nlm.nih.gov/pubmed/21397187"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Human Pumilio (hPUM) is a structurally well-analyzed RNA-binding protein that has been used recently for artificial RNA binding.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34541851",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "A family of RBPs, which is known as the Pumilio-FBF (PUF) family, is highly conserved among different species and has been associated with the undifferentiated and differentiated states of different cell lines",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32437472",
          "offsetInBeginSection": 247,
          "offsetInEndSection": 456
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " The RNA-binding domains of Pumilio/fem-3 mRNA binding factors (PUF domains) are programmable RNA binding scaffolds used to engineer artificial proteins that specifically modulate RNAs",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29490074",
          "offsetInBeginSection": 89,
          "offsetInEndSection": 273
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Pumilio is a member of the highly conserved PUF family of RNA-binding proteins that function as a developmental regulator in diverse animal species. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25896760",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Pumilio1 (Pum1) has been shown to play key roles in translational regulation of target mRNAs in many systems of diverse organisms. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30289101",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 243
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Human PUMILIO1 (PUM1) and PUMILIO2 (PUM2) are members of the PUMILIO/FBF (PUF) family that regulate specific target mRNAs posttranscriptionally.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21397187",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144
        }
      ],
      "id": "621fcaf93a8413c653000065",
      "type": "factoid",
      "body": "What is the function of the protein encoded by PUMILIO1?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34256819"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "CPX-351 (United States: Vyxeos®; Europe: Vyxeos® Liposomal), a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, is approved by the US FDA and the EMA for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34256819",
          "offsetInBeginSection": 12,
          "offsetInEndSection": 363
        }
      ],
      "id": "6211557b3a8413c65300000f",
      "type": "summary",
      "body": "What is CPX-351"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28341696"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "To identify novel coding association signals and facilitate characterization of mechanisms influencing glycemic traits and type 2 diabetes risk, we analyzed 109,215 variants derived from exome array genotyping together with an additional 390,225 variants from exome sequence in up to 39,339 normoglycemic individuals from five ancestry groups. We identified a novel association between the coding variant (p.Pro50Thr) in AKT2 and fasting plasma insulin (FI), a gene in which rare fully penetrant mutations are causal for monogenic glycemic disorders. The low-frequency allele is associated with a 12% increase in FI levels. This variant is present at 1.1% frequency in Finns but virtually absent in individuals from other ancestries. Carriers of the FI-increasing allele had increased 2-h insulin values, decreased insulin sensitivity, and increased risk of type 2 diabetes (odds ratio 1.05). In cellular studies, the AKT2-Thr50 protein exhibited a partial loss of function. We extend the allelic spectrum for coding variants in AKT2 associated with disorders of glucose homeostasis and demonstrate bidirectional effects of variants within the pleckstrin homology domain of AKT2.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28341696",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1179
        }
      ],
      "id": "6028f5851cb411341a0000ff",
      "type": "factoid",
      "body": "What is the prevalence of the inactivating AKT variant p.Pro50Thr in the Finnish population?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32804590",
        "http://www.ncbi.nlm.nih.gov/pubmed/32859585",
        "http://www.ncbi.nlm.nih.gov/pubmed/31033566",
        "http://www.ncbi.nlm.nih.gov/pubmed/31085175"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Ripretinib is a novel switch-control kinase inhibitor designed to inhibit a wide range of KIT and PDGFRA mutations.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32804590",
          "offsetInBeginSection": 185,
          "offsetInEndSection": 300
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "The KIT/PDGFRA Inhibitor Ripretinib Shows Signs of Activity in GIST.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32859585",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 68
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Both avapritinib and ripretinib are more potent and more specific against various KIT and PDGFRA mutations. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31033566",
          "offsetInBeginSection": 395,
          "offsetInEndSection": 503
        },
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31085175",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Ripretinib (DCC-2618) was designed to inhibit the full spectrum of mutant KIT and PDGFRA kinases found in cancers and myeloproliferative neoplasms, particularly in gastrointestinal stromal tumors (GISTs), in which the heterogeneity of drug-resistant KIT mutations is a major challenge. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31085175",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 286
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Ripretinib inhibits all tested KIT and PDGFRA mutants, and notably is a type II kinase inhibitor demonstrated to broadly inhibit activation loop mutations in KIT and PDGFRA, previously thought only achievable with type I inhibitors.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31085175",
          "offsetInBeginSection": 424,
          "offsetInEndSection": 656
        }
      ],
      "id": "6025e3a71cb411341a0000bc",
      "type": "list",
      "body": "Which mutations are inhibited by Ripretinib?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32760121",
        "http://www.ncbi.nlm.nih.gov/pubmed/32946794",
        "http://www.ncbi.nlm.nih.gov/pubmed/29120406",
        "http://www.ncbi.nlm.nih.gov/pubmed/28931603",
        "http://www.ncbi.nlm.nih.gov/pubmed/25665578"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Members of the family of pyrin and HIN domain containing (PYHIN) proteins play an emerging role in innate immunity.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32760121",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": " our data show that IFI16, PYHIN1 and MNDA restrict HIV-1 and other viral pathogens by interfering with Sp1-dependent gene expression and support an important role of nuclear PYHIN proteins in innate antiviral immunity.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32760121",
          "offsetInBeginSection": 1769,
          "offsetInEndSection": 1988
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Absent in melanoma 2 (AIM2) is a member of the PYHIN (pyrin and HIN domain-containing protein) family with important roles in sensing double-stranded DNA (dsDNA) and assembling the AIM2 inflammasome, which has wide-ranging, pro-inflammatory and pro-pyroptotic properties. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32946794",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 272
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Pattern recognition receptors such as nucleotide-binding oligomerization domain (NOD)-containing protein receptors (NLRs) and the pyrin and hematopoitic interferon-inducible nuclear protein (HIN) domain (PYHIN) receptors initiate the inflammatory response following cell stress or pathogenic challenge. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29120406",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 303
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Members of the IFN-inducible PYHIN protein family, such as absent in melanoma-2 and IFN-γ-inducible protein (IFI)16, bind dsDNA and form caspase-1-activating inflammasomes that are important in immunity to cytosolic bacteria, DNA viruses, or HIV. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28931603",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 247
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The human PYHIN proteins, AIM2, IFI16, IFIX, and MNDA, are critical regulators of immune response, transcription, apoptosis, and cell cycle.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25665578",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140
        }
      ],
      "id": "60490e321cb411341a000168",
      "type": "summary",
      "body": "What is known about the PYHIN proteins?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/1327232",
        "http://www.ncbi.nlm.nih.gov/pubmed/10992015",
        "http://www.ncbi.nlm.nih.gov/pubmed/2185802",
        "http://www.ncbi.nlm.nih.gov/pubmed/8765915"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The problem of the drug induced pulmonary toxicity (cytotoxic and non-cytotoxic drugs) is discussed.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1327232",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "ulmonary drug toxicity is increasingly being diagnosed as a cause of acute and chronic lung disease. Numerous agents including cytotoxic and noncytotoxic drugs have the potential to cause pulmonary toxicity",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10992015",
          "offsetInBeginSection": 1,
          "offsetInEndSection": 207
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Cytotoxic agents may cause interstitial or eosinophilic pneumonitis, alveolar proteinosis, pulmonary venous occlusive disease, pulmonary fibrosis, pneumothorax, or pulmonary oedema",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2185802",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "The cytotoxic drugs which are most often implicated in causing this are bleomycin, methotrexate, cyclophosphamide and busulfan. ",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8765915",
          "offsetInBeginSection": 1181,
          "offsetInEndSection": 1309
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Cytotoxic drugs are the most common cause of toxic lung disease.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8765915",
          "offsetInBeginSection": 1730,
          "offsetInEndSection": 1794
        }
      ],
      "id": "621ec0313a8413c65300005e",
      "type": "factoid",
      "body": "What class of drugs is commonly associated with Drug-induced interstitial lung disease (DIILD)?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16923466"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "In conclusion, because both grapefruit and pomegranate juice are known to inhibit intestinal cytochrome P450 3A4, this report suggests that pomegranate juice may increase the risk of rhabdomyolysis during rosuvastatin treatment, despite the fact that rosuvastatin is not known to be metabolized by hepatic P450 3A4.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16923466",
          "offsetInBeginSection": 365,
          "offsetInEndSection": 680
        }
      ],
      "id": "6206b399c9dfcb9c09000039",
      "type": "factoid",
      "body": "What pathological phenotype could potentially concomitant pomegranate juice and rosuvastatin use cause?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34864893"
      ],
      "snippets": [
        {
          "beginSection": "title",
          "endSection": "title",
          "text": "trfermikit: a tool to discover VNTR-associated deletions.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864893",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 57
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "We present trfermikit, a software tool designed to detect deletions larger than 50 bp occurring in Variable Number Tandem Repeats (VNTRs) using Illumina DNA sequencing reads. In such regions, it achieves a better trade-off between sensitivity and false discovery than a state-of-the-art structural variation (SV) caller, Manta, and complements it by recovering a significant number of deletions that Manta missed. trfermikit is based upon the fermikit pipeline, which performs read assembly, maps the assembly to the reference genome, and calls variants from the alignment.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864893",
          "offsetInBeginSection": 9,
          "offsetInEndSection": 582
        }
      ],
      "id": "621911323a8413c653000038",
      "type": "factoid",
      "body": "Which tool has been developed to discover VNTR-associated deletions?"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32382949",
        "http://www.ncbi.nlm.nih.gov/pubmed/32583848",
        "http://www.ncbi.nlm.nih.gov/pubmed/30815927"
      ],
      "snippets": [
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "In March 2020, oral tirabrutinib was approved in Japan for the treatment of recurrent or refractory primary central nervous system lymphoma. Tirabrutinib is also under regulatory review in Japan for the treatment of Waldenström\u0027s macroglobulinemia and lymphoplasmacytic lymphoma. Clinical development is underway in the USA, Europe and Japan for autoimmune disorders, chronic lymphocytic leukaemia, B cell lymphoma, Sjogren\u0027s syndrome, pemphigus and rheumatoid arthritis. This article summarizes the milestones in the development of tirabrutinib leading to the first approval of tirabrutinib for the treatment of recurrent or refractory primary central nervous system lymphoma in Japan.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32382949",
          "offsetInBeginSection": 420,
          "offsetInEndSection": 1106
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "CONCLUSION: These data indicate favorable efficacy of tirabrutinib in patients with relapsed/refractory PCNSL.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32583848",
          "offsetInBeginSection": 1570,
          "offsetInEndSection": 1680
        },
        {
          "beginSection": "abstract",
          "endSection": "abstract",
          "text": "Tirabrutinib was well tolerated and showed promising efficacy for B-cell NHL/CLL.",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30815927",
          "offsetInBeginSection": 1621,
          "offsetInEndSection": 1702
        }
      ],
      "id": "601d6fe11cb411341a000033",
      "type": "yesno",
      "body": "Is tirabrutinib effective for lymphoma?"
    }
  ]
}